WO2004050694A1 - Procedes de production de methionine - Google Patents

Procedes de production de methionine Download PDF

Info

Publication number
WO2004050694A1
WO2004050694A1 PCT/EP2002/013504 EP0213504W WO2004050694A1 WO 2004050694 A1 WO2004050694 A1 WO 2004050694A1 EP 0213504 W EP0213504 W EP 0213504W WO 2004050694 A1 WO2004050694 A1 WO 2004050694A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
nucleic acid
methionine
protein
acid molecule
Prior art date
Application number
PCT/EP2002/013504
Other languages
English (en)
Inventor
Markus Pompejus
Burkhard Kroeger
Hartwig Schroeder
Oskar Zelder
Gregor Haberhauer
Stefan Haefner
Corinna Klopprogge
Original Assignee
Basf Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Aktiengesellschaft filed Critical Basf Aktiengesellschaft
Priority to CN02829972.8A priority Critical patent/CN1694899B/zh
Priority to PCT/EP2002/013504 priority patent/WO2004050694A1/fr
Priority to EP02790458A priority patent/EP1567549A1/fr
Priority to BRPI0215958A priority patent/BRPI0215958B1/pt
Priority to JP2004556063A priority patent/JP2006521083A/ja
Priority to AU2002368410A priority patent/AU2002368410A1/en
Publication of WO2004050694A1 publication Critical patent/WO2004050694A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/12—Methionine; Cysteine; Cystine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/77—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Corynebacterium; for Brevibacterium

Definitions

  • Methionine is currently produced as a racemic mixture of DL- methionine by a well established chemical process. Most DL- methionine is being produced by variations of the same chemical procedure method involving toxic, dangerous, flammable, unstable, and highly odorous starting materials or intermediates .
  • the starting materials for the chemical synthesis are: acroiein, me- thylmercaptan and hydrogen cyanide.
  • the chemical synthesis in- volves the reaction of methylmercaptan and acroiein producing the intermediate 3-methylmercaptopropionaldehyde (MMP) .
  • the MMP reacts with hydrogen cyanide to form the 5- (2-methylthioethyl) hydantoin, which then can be hydrolyzed using 2 equivalents of caustics such as NaOH together with one half equivalent Na 2 C0 3 to yield sodium-DL-methioninate and one equivalent Na.C0 3 one equivalent NH. and one half equivalent CO..
  • the sodium-DL-methioninate is neutralized with 1.5 equiv. sulfuric acid and 1 equiv.Na.C0 3 to yield DL- methionine Na, 2S0 mask4 and CO,2. It is obvious that such a chemical process yields a large molar excess of unused salts in comparison to the amount of methionine that is produced. This fact poses an economic and ecological challenge.
  • Fermentative processes are usually based on cultivating microor- ganisms on nutrients including carbohydrate source (e.g. , sugars such as glucose fructose or saccharose), nitrogen sources (e.g., ammonia) and sulfur sources (e.g., sulfate or thiosulfate) together with other necessary media components.
  • carbohydrate source e.g. , sugars such as glucose fructose or saccharose
  • nitrogen sources e.g., ammonia
  • sulfur sources e.g., sulfate or thiosulfate
  • Methionine can be produced in organisms such as E.
  • the cell In order to maintain a balance between the various parts of this extremely complex metabolic network, the cell employs a finely-tuned regulatory network. By regulating enzyme synthesis and enzyme activ- ity, either independently or simultaneously, the cell is able to control the activity of disparate metabolic pathways to reflect the changing needs of the cell. The induction or repression of enzyme synthesis may occur at either the level of transcription or translation, or both. Gene expression in prokaryotes is regulated by several mechanisms at the level of transcription (for review see e.g., Lewin, B (1990) Genes IV, Part 3: "Controlling prokaryotic genes by transcription", Oxford University Press: Oxford, p.
  • Their activity can, for example, be regulated by the binding of low molecular weight compounds to the DNA-binding protein, thereby stimulating or inhibiting the binding of these proteins to the appropriate binding site on the DNA (see, for example, Helmann, J.D. and Cham- berlin, M.J. (1988) "Structure and function of bacterial sigma factors.” Ann. Rev. Biochem. 57: 839-872; Adhya, S. (1995) "The lac and gal operons today” and Boos, W. et al . , "The maltose system.”, both in: Regulation of Gene Expression in Escherichia coli (Lin, E.C.C. and Lynch, A.S., eds .
  • Up- or down-regulation of gene transcription and translation may be governed by the cellular and extracellular levels of various factors, such as substrates, catabolites, and end products.
  • factors such as substrates, catabolites, and end products.
  • the expression of genes encoding enzymes necessary for the activity of a particular pathway is induced by high lev- els of substrate molecules for that pathway.
  • gene expression tends to be repressed when there exist high intracellular levels of the end product of the pathway (Snyder, L. and Champness, W. (1997) The Molecular Biology of Bacteria ASM: Washington) .
  • Gene expression may also be regulated by other external and internal factors, such as environmental conditions (e.g., heat, oxidative stress, or starvation; see, for example, Lin, E.C.C. and Lynch, A.S., eds. (1995) Regulation of Gene Expression in Escherichia coli . Chapman & Hall: New York) .
  • the invention provides novel methods for modulate the biosynthesis of fine chemicals preferably sulfur-containing compounds like e.g., methionine. It has been found that the metabolic regulatory ( "MR" ) molecules of the invention are involved in biosynthesis of a fine chemical, preferably sulfur-containing compounds like e.g., methionine.
  • MR metabolic regulatory
  • the MR molecule RXA00655 is a negative regulator, e . g. , transcriptional regulator, of methionine biosynthesis, cysteine biosynthesis, and/or the sulfur reduction pathway. It has also been found that the MR molecule RXN02910 is a positive regulator, e.g., transcriptional regula- tor, of methionine biosynthesis.
  • the nucleotide sequence of RXA00655 is set forth herein as SEQ ID N0:1 and the polypeptide sequence of RXA00655 is set forth herein as SEQ ID NO: 2.
  • the nucleotide sequence of RXN02910 is set forth herein as SEQ ID NO: 5 and the polypeptide sequence of RXA00655 is set forth herein as SEQ ID NO: 6.
  • Homologous proteins of RXA00655 are set forth herein as SEQ ID NO: 19, 21 and 23.
  • the nucleotide sequence of said RXN02910 homologous proteins is set forth herein as SEQ ID NO: 18, 20 and 22.
  • Modulation of the expression of the MR nucleic acids of the invention e. g. , increasing expression of the RXN02910 nucleic acid molecule or increasing the activity of the RXN02910 protein, suppressing expression of the RXA00655 nucleic acid mole- cule or suppressing the activity of the RXA00655 protein, or modification of the sequence of the MR nucleic acid molecules of the invention to alter the activity of the MR nucleic acid molecule, can be used to modulate, e . g. , increase, the production of a fine chemical, e . g.
  • methionine, cysteine, and/or other com- pounds of the methionine biosynthetic pathway, the sulfur reduction pathway, and/or the cysteine biosynthetic pathway from a microorganism e . g. , to improve the yield or production of a fine chemical, e. g. , methionine or other compounds of the methionine biosynthetic pathway, from a Corynebacterium or Brevi- bacterium species
  • increasing the expression or activity of the RXN02910 nucleic acid or protein and suppression of the expression or activity of the RXA00655 nucleic acid or protein, in combination can be used to modulate, e . g.
  • a fine chemical e.g., methion- ine, cysteine, and/or other compounds of the methionine biosynthetic pathway, the sulfur reduction pathway, and/or the cysteine biosynthetic pathway from a microorganism (e.g., Corynebacterium or Brevibacterium species) .
  • a microorganism e.g., Corynebacterium or Brevibacterium species
  • the present invention features methods of modulating production of a sulfur-containing compound by a microorganism comprising culturing a microorganism with modulated expression or activity of at least one regulator of methionine biosynthesis under conditions such that production of a sulfur-containing compound is modulated.
  • said sulfur-containing compound is selected from the group consisting of methionine, cysteine, S- adenosylmethionine and homocycsteine.
  • production of said sulfur-containing compound e.g, methionine
  • methionine is increased
  • the present invention features methods of increasing production of a sulfur-containing compound by a microorganism comprising culturing a microorganism which overexpresses a positive regulator of methionine biosynthesis, e.g., RXN02910, under conditions such that production of the sulfur-containing compound is increased. Furthermore, the present invention features methods of increasing production of a sulfur-containing compound by a microorganism comprising culturing a microorganism which underex- presses a negative regulator of methionine biosynthesis, e . g. , RXA00655, under conditions such that production of the sulfur- containing compound is increased.
  • the present invention features methods of producing methionine as well as other compounds of the methionine biosynthetic pathway.
  • Such methods include culturing microorganisms overexpressing the RXN02910 gene product under conditions such that methionine, or other compounds of the methionine biosynthetic pathway, are produced.
  • Such methods also include culturing microorganisms with inhibited expression of the RXA00655 gene product such that methionine, or other compounds of the methionine biosynthetic pathway, the sulfur reduction pathway, and/or the cysteine biosynthetic pathway are produced.
  • the present invention also provides methods for producing a fine chemical comprising culturing microorganisms overexpressing the RXN02910 gene product in combination with microorganisms with inhibited expression of the RXA00655 gene product.
  • the MR proteins are capable of, for example, performing a function involved in the transcriptional, translational, or post- translational regulation of proteins important for the normal metabolic functioning of cells.
  • the nucleic acid molecules of the invention may be utilized in the genetic engineering of this organism to make it a better or more efficient producer of a fine chemical, e . g. , methionine.
  • This improved yield, production and/or efficiency of production of a fine chemical may be due to a direct effect of manipulation of a gene of the invention, e . g. , RXA00655 or RXN02910, or it may be due to an indirect effect of such manipulation.
  • alterations in C. glutamicum MR proteins which normally regulate the yield, production and/or efficiency of production of the methionine metabolic pathways may have a direct impact on the overall production or rate of production of a fine chemical, e . g.
  • methionine, cysteine, and/or other compounds of the methionine biosynthetic pathway, the sulfur reduction pathway, and/or the cysteine biosynthetic pathway from this organism Alterations in the proteins involved in the methionine metabolic pathway may also have an indirect impact on the yield, production and/or efficiency of production of a desired fine chemical, e . g. , methionine. Regulation of metabolism is necessarily complex, and the regulatory mechanisms governing different pathways may intersect at multiple points such that more than one pathway can be rapidly adjusted in accordance with a particular cellular event.
  • the nucleic acid and protein molecules of the invention may be utilized to directly improve the yield, production, and/or efficiency of production of methionine from Corynebacterium glutamicum.
  • one or more of the regulatory proteins of the invention may be manipulated such that its function or expression is modulated.
  • the mutation of an MR protein e. g. , RXA00655
  • RXA00655 which is involved in the repression of transcription of a gene, e . g.
  • the metY gene encoding a polypeptide which is required for the biosynthesis of an amino acid, e. g.
  • methion- ine such that it no longer is able to repress transcription may result in an increase in production of that amino acid.
  • the alteration of activity of an MR protein resulting in increased translation or activating posttranslational modification of a C. gluta-nicum protein involved in the biosynthesis of a desired fine chemical, e. g. , methionine may in turn increase the production of that chemical.
  • the opposite situation may also be of benefit: by increasing the repression of transcription or translation, or by posttranslational negative modification of a C. glutamicum protein involved in the regulation of a degrada- tive pathway for a compound, one may increase the production of this chemical. In each case, the overall yield or rate of production of the desired fine chemical may be increased.
  • Such alterations in the protein and nucleotide molecules of the invention may improve the yield, production, and/or efficiency of production of fine chemicals, e . g. , methionine, through indirect mechanisms.
  • the metabolism of any one compound is necessarily intertwined with other biosynthetic and degradative pathways within the cell, and necessary cofactors, intermediates, or substrates in one pathway are likely supplied or limited by another such pathway. Therefore, by modulating the activity of one or more of the regulatory pro- teins of the invention, the production or efficiency of activity of another fine chemical biosynthetic or degradative pathway may be impacted.
  • the manipulation of one or more regulatory proteins may increase the overall ability of the cell to grow and multiply in culture, particularly in large-scale fermenta- tive culture, where growth conditions may be suboptimal .
  • an MR protein of the invention which would normally cause a repression in the biosynthesis of nucleotides in response to suboptimal extracellular supplies of nutrients (thereby preventing cell division) such that it is decreased in repressor ability, one may increase the biosynthesis of nucleotides and perhaps increase cell division.
  • Changes in MR proteins which result in increased cell growth and division in culture may result in an increase in yield, production, and/or efficiency of production of one or more desired fine chemicals from the culture, due at least to the increased number of cells producing the chemical in the culture.
  • the invention provides novel transgenic expression cassettes comprising in combination with a regulatory sequence a nucleic acid molecule coding for a metabolic pathway protein [ (MR) protein] or a fragment thereof, wherein said regulatory sequence is capable of mediating expression of said nucleic acid molecule, preferably in a microorganism.
  • said regulatory sequence is a promoter heterologous with regard to said nucleic acid molecule.
  • the regulatory sequence is a promoter sequence functional in Corynebacterium glutamicum.
  • MR proteins are capable of, for example, performing an enzymatic step involved in the transcriptional, translational, or posttranslational regulation of metabolic pathways in C. glutamicum.
  • Nucleic acid molecules encoding an MR protein are referred to herein as MR nucleic acid molecules.
  • the MR protein participates in the transcriptional, translational, or posttranslational regulation of one or more metabolic pathways .
  • the MR nucleic acid molecule is selected from the group consisting of:
  • nucleic acid molecule comprising a nucleotide sequence which is at least 60% identical to the nucleotide sequence of SEQ ID N0:1, SEQ ID NO: 5, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, or SEQ ID NO: 22, or a complement thereof;
  • nucleic acid molecule comprising a fragment of at least 30 nucleotides of a nucleic acid comprising the nucleotide se- quence of SEQ ID N0:1, SEQ ID NO: 5, SEQ ID NO: 16, SEQ ID NO:
  • nucleic acid molecule which encodes a polypeptide comprising an amino acid sequence at least about 60% identical to the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, or SEQ ID NO: 23; and
  • nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, or SEQ ID NO:
  • fragment comprises at least 10 contiguous amino acid residues of the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, or SEQ ID NO: 23,
  • the transgenic expression cassette may comprise the nucleic acid molecule coding for the MR protein (e.g., RXA00655 or RXA02910) in antisense or sense orientation with regard to said promoter sequence.
  • the nucleic acid molecule coding for the MR protein encodes a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, or SEQ ID NO: 23.
  • said nucleic acid molecule comprises the nucleotide sequence set forth in SEQ ID NO:l, SEQ ID NO : 5 , SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, or SEQ ID NO: 22.
  • the nucleic acid molecule may also code for a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, or SEQ ID NO: 23.
  • Another aspect of the invention pertains to a vector comprising at least one of the inventive transgenic expression cassettes.
  • the vector is an expression vector.
  • Yet another aspect of the invention pertains to a host cell transfected or transformed with at least one of the transgenic expression cassettes of this invention or at least one of the inventive vectors or expressionvectors .
  • the host cell belongs to the genus Corynebacterium or Brevi-bacterium.
  • such a host cell is used to produce an MR pro- tein by culturing the host cell in a suitable medium. The MR protein can be then isolated from the medium or the host cell.
  • Yet another aspect of the invention pertains to a genetically altered microorganism in which an MR gene has been introduced or altered.
  • the genome of the microorganism has been altered by introduction of a nucleic acid molecule of the invention encoding wild-type or mutated MR sequence as a transgene.
  • an endogenous MR gene within the genome of the microorganism has been altered, e. g. , functionally disrupted, by homologous recombination with an altered MR gene.
  • an endogenous or introduced MR gene in a microorganism has been altered by one or more point mutations, deletions, or inversions, but still encodes a functional MR protein.
  • one or more of the regulatory regions (e.g., a promoter, repressor, or inducer) of an MR gene in a microorganism has been altered (e.g., by deletion, truncation, inversion, or point mutation) such that the expression of the MR gene is modulated.
  • the microorganism belongs to the genus Corynebacterium or Brevibac terium, with Corynebacterium glutamicum being particularly preferred.
  • the microorganism is also utilized for the production of a desired compound, such as an amino acid, with methionine, being particularly preferred.
  • Another aspect of the invention pertains to a method for producing a fine chemical.
  • This method involves the culturing of a cell containing a vector directing the expression of an MR nu- cleic acid molecule of the invention, such that a fine chemical is produced.
  • this method further includes the step of obtaining a cell containing such a vector, in which a cell is transfected with a vector directing the expression of an MR nucleic acid.
  • this method further includes the step of recovering the fine chemical, e . g. , methionine, from the culture.
  • the cell is from the genus Corynebacterium or Brevi-bacterium, or is selected from those strains set forth in Table 1.
  • Another aspect of the invention pertains to methods for modulating production of a molecule from a microorganism. Such methods include contacting the cell with an agent which modulates MR protein activity or MR nucleic acid expression such that a cell associated activity is altered relative to this same activity in the absence of the agent.
  • the cell is modulated for one or more C. glutamicum metabolic pathway regulatory systems, such that the yields or rate of production of a desired fine chemical, e . g. , methionine, by this microorganism is improved.
  • the agent which modulates MR protein activity can be an agent which stimulates MR protein activity or MR nucleic acid expression.
  • agents which stimulate MR protein activity or MR nucleic acid expression include small molecules, active MR proteins, and nucleic acids encoding MR proteins that have been introduced into the cell.
  • agents which inhibit MR activity or expression include small molecules and antisense MR nucleic acid molecules.
  • Another aspect of the invention pertains to methods for modulat- ing yields of a desired compound from a cell, involving the introduction of a wild-type or mutant MR gene into a cell, either maintained on a separate plasmid or integrated into the genome of the host cell. If integrated into the genome, such integration can be random, or it can take place by homologous recombi- nation such that the native gene is replaced by the introduced copy, causing the production of the desired compound from the cell to be modulated.
  • said yields are increased.
  • said chemical is a fine chemical.
  • said fine chemical is an amino acid.
  • said amino acid is methionine.
  • Figure 1 depicts the principal of a self-cloning technique based on homologous recombination which is used for preparation of a Corynebacterium glutamicum strain deficient in the negative regu- lator of methionine biosynthesis (RXA00655, set forth as SEQ ID NO : 1) .
  • the present invention provides metabolic regulatory (MR) nucleic acid and protein molecules, e. g. , RXA00655 and RXN02910 nucleic acid and protein molecules, which are involved in the regulation of metabolism in microorganisms, e . g. , Corynebacterium glutamicum, including regulation of fine chemical metabolism, e . g. , methionine biosynthesis by, e . g. , transcriptional regulation of genes, e . g. , the metY gene, involved in the methionine biosynthetic pathway, the sulfur reduction pathway, and/or the cysteine biosynthetic pathway.
  • MR metabolic regulatory
  • the present invention features methods based on manipulation of the methionine biosynthetic pathway, the sulfur reduction pathway, and/or the cysteine biosynthetic pathway in a microorganism such that a fine chemical, e . g. , a sulfur- containing compound, e . g. , methionine, cysteine, and/or other compounds of the methionine biosynthetic pathway, the sulfur reduction pathway, and/or the cysteine biosynthetic pathway are produced.
  • a fine chemical e . g. , a sulfur- containing compound, e . g. , methionine, cysteine, and/or other compounds of the methionine biosynthetic pathway, the sulfur reduction pathway, and/or the cysteine biosynthetic pathway are produced.
  • methionine biosynthetic pathway includes a pathway involving methionine biosynthetic enzymes (e . g. , polypeptides encoded by biosynthetic enzyme-encoding genes), compounds (e.g., precursors, substrates, intermediates or products) , cofactors and the like, utilized in the formation or synthesis of methionine.
  • Methionine is an amino acid nutritionally required by mam- mals. Bacteria synthesize their own methionine from amino acids and biosynthetic intermediates thereof ( Escherichia Coli and Salmonella : Cellular and Molecular Biology, Neidhardt, Frederick C. Curtiss, Roy III Ingraham, John L.
  • cyste biosynthetic pathway includes a pathway involving cysteine biosynthetic enzymes (e . g. , polypeptides encoded by biosynthetic enzyme- encoding genes), compounds ( e . g. , precursors, substrates, intermediates or products) , cofactors and the like, utilized in the formation or synthesis of cysteine.
  • cysteine biosynthetic enzymes e . g. , polypeptides encoded by biosynthetic enzyme- encoding genes
  • compounds e . g. , precursors, substrates, intermediates or products
  • cofactors and the like utilized in the formation or synthesis of cysteine.
  • sulfur reduction pathway includes a pathway involving enzymes which function to metabolize inorganic compounds such as sulfur and derivatives thereof.
  • RXA00655 is a negative regulator, e . g. , a transcriptional regulator, of fine chemical biosynthesis, e. g. , methionine biosynthesis. Accordingly, suppression or inhibition of the expression of the RXA00655 gene or knockout of the RXA00655 gene leads to increased production of a fine chemical, e . g. , methionine, cysteine, and/or other compounds of the methionine biosynthetic pathway, the sulfur reduction pathway, and/or the cysteine biosynthetic pathway, in microorganisms, e. g. , Corynebacterium glutamicum.
  • a fine chemical e. g. , methionine, cysteine, and/or other compounds of the methionine biosynthetic pathway, the sulfur reduction pathway, and/or the cysteine biosynthetic pathway, in microorganisms, e. g. , Corynebacterium glutamicum.
  • Introduction of a mutation which reduces or inhibits expression of the RXA00655 gene or activity of the RXA00655 polypeptide also leads to increased production of a fine chemical, e . g. , methionine, cysteine, and/or other compounds of the methionine biosynthetic pathway, the sulfur reduction pathway, and/or the cysteine biosynthetic pathway, in microorganisms, e . g. , Corynebacteri um glutamicum .
  • RXN02910 is a positive regulator, e.g., a transcriptional regulator, of fine chemical biosynthesis, e. g. , methionine biosynthesis. Accordingly, overexpression of the RXN02910 gene leads to increased production of methionine and other compounds of the methionine biosynthetic pathway in microorganisms, e . g. , Corynebacterium glu tamicum. Introduction of a mutation which increases expression of the RXN02910 gene or activity of the RXN02910 polypeptide also leads to increased production of methionine and other compounds of the methionine biosynthetic pathway in microorganisms, e . g. , Corynebacterium glu tamicum .
  • suppression or inhibition of the expression of RXA00655 or knock-out of the RXA00655 gene in combination with overexpression of the RXN02910 gene in a microorganism also leads to increased production of a fine chemical, e . g. , methionine, cysteine, and/or other compounds of the methionine biosynthetic pathway, the sulfur reduction pathway, and/or the cys- teine biosynthetic pathway, by the microorganism.
  • a fine chemical e . g. , methionine, cysteine, and/or other compounds of the methionine biosynthetic pathway, the sulfur reduction pathway, and/or the cys- teine biosynthetic pathway
  • culture of microorganisms with suppressed or inhibited expression of RXA00655 or microorganisms with a knock-out of the RXA00655 gene together with microorganisms which overexpress RXN02910 gene also leads to increased production of a fine chemical, e . g. , methionine, cysteine, and/or other compounds of the methionine biosynthetic pathway, the sulfur reduction pathway, and/or the cysteine biosynthetic pathway, by the microorganism.
  • a fine chemical e . g. , methionine, cysteine, and/or other compounds of the methionine biosynthetic pathway, the sulfur reduction pathway, and/or the cysteine biosynthetic pathway
  • one aspect the present invention features methods of producing fine chemicals, e . g. , methionine or other compounds of the methionine biosynthetic pathway, which include culturing a microorganism which overexpresses RXN02910 under conditions such that a fine chemical, e . g. , methionine or other compounds of the methionine biosynthetic pathway are produced.
  • a microorganism which overexpresses RXN02910 includes a microorganism which has been manipulated such that RXN02910 is overexpressed.
  • overexpressed includes expression of a gene product (e.g., the RXN02910 gene product) at a level greater than that expressed prior to manipulation of the microorganism or in a comparable microorganism which has not been manipulated.
  • a gene product e.g., the RXN02910 gene product
  • overexpression of a particular gene includes expression which is 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or greater than expression of the gene by an organism which has not been manipulated to overexpress the particular gene. Ranges and identity values intermediate to the above percentages are encompassed by the present in- vention.
  • the microorganism can be genetically manipulated (e.g., genetically engineered) to overexpress a level of gene product greater than that expressed prior to manipulation of the microorganism or in a comparable microorganism which has not been manipulated.
  • genetically manipulated e.g., genetically engineered
  • Genetic manipulation can in- elude, but is not limited to, altering or modifying regulatory sequences or sites associated with expression of a particular gene (e.g., by adding strong promoters, inducible promoters or multiple promoters or by removing regulatory sequences such that expression is constitutive) , modifying the chromosomal location of a particular gene, altering nucleic acid sequences adjacent to a particular gene such as a ribosome binding site, increasing the copy number of a particular gene, modifying proteins (e.g., regulatory proteins, suppressors, enhancers, transcriptional ac- tivators and the like) involved in transcription of a particular gene and/or translation of a particular gene product, or any other conventional means of deregulating expression of a particular gene routine in the art (including but not limited to use of antisense nucleic acid molecules, for example, to block expression of repressor proteins) .
  • altering or modifying regulatory sequences or sites associated with expression of a particular gene e.g., by adding strong
  • the present invention features a method of producing a fine chemical, e . g. , methionine, cysteine, and/or other compounds of the methionine biosynthetic pathway, the sulfur reduction pathway, and/or the cysteine biosynthetic pathway, which includes culturing a microorganism which has suppressed or inhibited RXA00655 expression under conditions such that a fine chemical, e . g. , methionine, cysteine, and/or other compounds of the methionine biosynthetic pathway, the sulfur reduction pathway, and/or the cysteine biosynthetic pathway, are produced.
  • a microorganism which has suppressed RXA00655 expression includes a microorganism which has been manipulated such that RXA00655 expression is suppressed or inhibited.
  • suppression of expression includes expression of a gene product (e.gr., the RXA00655 gene product or the RXN02910 gene product) at a level lower than that expressed prior to manipulation of the microorganism or in a comparable microorganism which has not been manipulated.
  • suppression or inhibition of gene expression includes manipulation of a microorganism such that the gene is no longer expressed.
  • underexpression of a particular gene includes expres- sion which is 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, less than expression of the gene by an organism which has not been manipulated to underexpress the particular gene. Ranges and identity values intermediate to the above percentages are encompassed by the present invention.
  • the microor- ganism can be genetically manipulated (e.g., genetically engineered) to express a level of gene product lesser than that expressed prior to manipulation of the microorganism or in a comparable microorganism which has not been manipulated.
  • Genetic manipulation can include, but is not limited to, altering or modifying regulatory sequences or sites associated with expression of a particular gene, modifying the chromosomal location of a particular gene, altering nucleic acid sequences adjacent to a particular gene such as a ribosome binding site, decreasing the copy number of a particular gene, modifying proteins (e.g., regulatory proteins, suppressors, enhancers, transcriptional activators and the like) involved in transcription of a particular gene and/or translation of a particular gene product, use of an- tisense nucleic acid molecules, knock-out of the target gene, or any other conventional means of deregulating expression of a particular gene routine in the art.
  • a microorganism which is deficient in RXA00655 gene expression or RXN02910 gene expression includes a microorganism which has suppressed or inhibited RXA00655 or RXN02910 expression.
  • the present invention features a method of producing a fine chemical, e. g. , methionine, which includes culturing a microorganism which has increased RXN02910 activity un- der conditions such that a fine chemical, e.g., methionine, is produced.
  • a "microorganism which has increased RXN02910 activity” includes a microorganism which has been manipulated such that RXN02910 activity is increased.
  • the present invention features a method of producing a fine chemical, e.g., methionine, cysteine, and/or other compounds of the methionine biosynthetic pathway, the sulfur reduction pathway, and/or the cysteine biosynthetic pathway, which includes culturing a microorganism which has decreased RXA00655 activity under conditions such that a fine chemical, e.g., methionine, cysteine, and/or other compounds of the methionine biosynthetic pathway, the sulfur reduction pathway, and/or the cysteine biosynthetic pathway, is produced.
  • a "microorganism which has decreased RXA00655 activity” includes a mi- croorganism which has been manipulated such that RXA00655 activity is inhibited or suppressed.
  • RXN02910 activity includes any activity which results in fine chemical biosynthesis, e. g. , methionine biosynthesis.
  • RXN02910 activity includes, but is not limited to, positive regulation of the methionine biosynthetic pathway resulting in methionine biosynthesis or biosynthesis of other compounds of the methionine biosynthetic pathway.
  • Positive regulation of the methionine biosynthetic pathway may be by any means, including, but not limited to, transcriptional and translational regulation as well as protein regulation, via, e . g. , protein binding.
  • Increased activity includes activity at a level higher than that demonstrated prior to manipulation of the microorganism or in a comparable microorganism which has not been manipulated.
  • RXA00655 activity includes any activity which results in fine chemical biosynthesis, e.g., methionine biosynthesis.
  • An example of RXA00655 activity includes, but is not limited to, negative regulation of the methionine biosynthetic pathway, the sulfur reduction pathway, and/or the cysteine biosynthetic pathway as described in Escherichia Coli and Salmonella : Cellular and Molecular Biology, Neidhardt, Frederick C. Curtiss, Roy III Ingraham, John L. Eds, 2nd ed.
  • Negative regulation of the methionine biosynthetic pathway, the sulfur reduction pathway, and/or the cysteine biosynthetic pathway may be by any means, including, but not limited to transcriptional and translational regulation as well as protein regulation, via, e.g., protein binding.
  • Decreased or suppressed activity includes activity at a lower higher than that demon- strated prior to manipulation of the microorganism or in a comparable microorganism which has not been manipulated.
  • the present invention features methods of increasing production of a sulfur-containing compound by a microorganism comprising culturing a microorganism which overexpresses a positive regulator of methionine biosynthesis, e . g. , RXN02910, under conditions such that production of the sulfur-containing compound is increased.
  • the present invention also features methods of increasing production of a sulfur-containing compound by a microorgan- ism comprising culturing a microorganism which underexpresses a negative regulator of methionine biosynthesis, e . g. , RXA00655, under conditions such that production of the sulfur-containing compound is increased.
  • sulfur-containing compound includes any compound which contains sulfur or a derivative thereof.
  • Sulfur-containing compounds include amino acids, including, but not limited to, methionine, cysteine, S-adenosylmethionine, and homocycsteine .
  • the nucleotide sequence of RXA00655 is set forth herein as SEQ ID N0:1 and the polypeptide sequence of RXA00655 is set forth herein as SEQ ID NO : 2.
  • the nucleotide sequence of RXN02910 is set forth herein as SEQ ID NO: 5 and the polypeptide sequence of RXA00655 is set forth herein as SEQ ID NO: 6.
  • Homologous protein of RXA00655 are set forth herein as SEQ ID NO: 19, 21 and 23.
  • the nucleotide sequence of said RXN02910 homologous proteins is set forth herein as SEQ ID NO: 18, 20 and 22.
  • SEQ ID N0s:16 and 17 represent mutated RXN02910 nucleic acid and amino acid sequences, respectively.
  • the RXN02910 molecule depicted in SEQ ID NO: 16 contains a single nucleotide change from a guanine (G) to an adenine (A) at nucleotide residue 556 in the coding region, which results in a change from an aspartic acid (D) to an asparagine (N) at amino acid residue 186 of the encoded protein, set forth as SEQ ID NO: 17.
  • This polymorphism may cause modulation of regulation of fine chemical biosynthesis, e.g., methionine biosynthesis by RXN02910, e.g., decreased methionine biosynthesis.
  • the molecules of the invention may be utilized in the modulation of production of fine chemicals, e . g. , methionine, from microorganisms, such as C. glutamicum, either directly (e.g., where modulation of the activity of a methionine biosynthesis regulatory protein has a direct impact on the yield, production, and/or efficiency of production of methionine from that organism) , or may have an indirect impact which nonetheless results in an increase in yield, production, and/or efficiency of production of the desired compound ( e . g.
  • the term 'fine chemical' is art-recognized and includes molecules produced by an organism which have applications in various industries, such as, but not limited to, the pharmaceutical, agriculture, and cosmetics industries.
  • Such compounds include or- ganic acids, such as tartaric acid, itaconic acid, and diamino- pimelic acid, both proteinogenic and non-proteinogenic amino acids, purine and pyrimidine bases, nucleosides, and nucleotides (as described e . g. in Kuninaka, A. (1996) Nucleotides and related compounds, p. 561-612, in Biotechnology vol. 6, Rehm et al . , eds.
  • VCH VCH: Weinheim, and references contained therein
  • lip- ids both saturated and unsaturated fatty acids (e . g. , arachi- donic acid), diols ( e . g. , propane diol, and butane diol) , carbohydrates (e.g., hyaluronic acid and trehalose) , aromatic com- pounds (e.g., aromatic amines, vanillin, and indigo), vitamins and cofactors (as described in Ullmann's Encyclopedia of Industrial Chemistry, vol. A27, "Vitamins", p. 443-613 (1996) VCH: Weinheim and references therein; and Ong, A.S., Niki, E. & Packer, L.
  • the present invention is based, at least in part, on the functional characterization of molecules of previous unknown function, referred to herein as MR nucleic acid and protein mole- cules, e . g. , RXA00655 nucleic and protein molecules and RXN02910 nucleic acid and protein molecules, which regulate or modulate one or more metabolic pathways in C. glutamicum, e.g., the methionine biosynthesis pathway.
  • RXA00655 is a negative regulator of the methionine biosynthetic pathway, the sulfur reduction pathway, and the cysteine biosynthetic pathway
  • RXN02910 is a positive regulator of methionine biosynthesis. Accordingly, the present invention features methods of producing a fine chemical, e .
  • methionine, cysteine, and/or other compounds of the methionine biosynthetic pathway g., methionine, cysteine, and/or other compounds of the methionine biosynthetic pathway, the sulfur reduction path- way, and/or the cysteine biosynthetic pathway and modulating production of a fine chemical, e.g., methionine, cysteine, and/or other compounds of the methionine biosynthetic pathway, the sulfur reduction pathway, and/or the cysteine biosynthetic pathway.
  • Such methods include culturing microorganisms overex- pressing the RXN02910 gene product or with increased RXN02910 activity under conditions such a fine chemical, e.g., methionine, cysteine, and/or other compounds of the methionine biosynthetic pathway, the sulfur reduction pathway, and/or the cysteine biosynthetic pathway is produced.
  • a fine chemical e.g., methionine, cysteine, and/or other compounds of the methionine biosynthetic pathway, the sulfur reduction pathway, and/or the cysteine biosynthetic pathway is produced.
  • Such methods' also in- elude culturing microorganisms with inhibited expression of the RXA00655 gene product or inhibited RXA00655 activity such that a fine chemical, e. g.
  • methionine, cysteine, and/or other compounds of the methionine biosynthetic pathway, the sulfur reduc- tion pathway, and/or the cysteine biosynthetic pathway is produced.
  • the present invention also provides methods for producing a fine chemical, e.g., methionine, comprising culturing microorganisms overexpressing the RXN02910 gene product and simultane- ously exhibiting an inhibited expression of the RXA00655 gene product or inhibited RXA00655 activity.
  • the present invention also provides methods for producing a fine chemical, e.g., methionine, comprising culturing microorganisms overexpressing the RXN02910 gene product in combination with microor- ganisms with inhibited expression of the RXA00655 gene product or inhibited RXA00655 activity.
  • a fine chemical e.g., methionine
  • the MR molecules of the invention transcrip- tionally, translationally, or posttranslationally regulate a metabolic pathway in C. glutamicum.
  • the activity of the MR molecules of the present invention to regulate one or more C. glutamicum metabolic pathways has an impact on the production of a desired fine chemical, e. g. , methionine, by this organism.
  • the MR molecules of the invention are modulated in activity, such that the C. glutamicum metabolic pathways which the MR proteins of the invention regulate are modulated in efficiency or output, which either directly or indirectly modulates the yield, production, and/or efficiency of production of a desired fine chemical, e.g., methionine, by C. glutamicum.
  • MR protein or “MR polypeptide” includes proteins which transcriptionally, translationally, or posttranslationally regulate a metabolic pathway in C. glut m cum.
  • MR gene or “MR nucleic acid sequence” include nucleic acid sequences encoding an MR protein, which consist of a coding region and also corresponding untranslated 5' and 3' sequence regions.
  • production or “productivity” are art-recognized and include the concentration of the fermentation product (for exam- pie, the desired fine chemical) formed within a given time and a given fermentation volume (e.g., kg product per hour per liter) .
  • the term "efficiency of production” includes the time required for a particular level of production to be achieved (for example, how long it takes for the cell to attain a particular rate of output of a fine chemical).
  • yield includes the efficiency of the conversion of the carbon source into the product (i.e., methionine). This is generally written as, for example, kg product per kg carbon source.
  • degradation or a “degradation pathway” are art- recognized and include the breakdown of a compound, preferably an organic compound, by a cell to degradation products (generally speaking, smaller or less complex molecules) in what may be a multistep and highly regulated process.
  • metabolism is art-recognized and includes the totality of the biochemical reactions that take place in an organism.
  • the metabolism of a particular compound, then, (e . g. , the metabolism of an amino acid such as glycine) comprises the overall biosynthetic, modification, and degradation pathways in the cell related to this compound.
  • regulation is art-recognized and includes the activity of a protein to govern or modulate the activity of another protein.
  • transcriptional regulation is art-recognized and includes the activity of a protein to impede or activate the conversion of a DNA encoding a target protein to mRNA.
  • translational regulation is art- recognized and includes the activity of a protein to impede or activate the conversion of an mRNA encoding a target protein to a protein molecule.
  • posttranslational regulation is art-recognized and includes the activity of a protein to impede or improve the activity of a target protein by covalently modifying the target protein (e.g., by methylation, glucosylation, or phosphorylation, or by binding the target protein) .
  • the MR molecules of the invention are capable of modulating the production of a desired molecule, such as a fine chemical, e.g., methionine, in a microorganism such as C. glutamicum.
  • a desired molecule such as a fine chemical, e.g., methionine
  • a microorganism such as C. glutamicum.
  • one or more of the regulatory proteins of the invention may be manipulated such that its function is modulated.
  • a biosynthetic enzyme may be improved in efficiency, or its allosteric control region destroyed such that feedback inhibition of production of the compound is prevented.
  • a degradative enzyme may be deleted or modified by substitution, deletion, or addition such that its degradative activity is lessened for the desired compound without impairing the viability of the cell.
  • the overall yield or rate of production of one of these desired fine chemicals may be increased. It is also possible that such alterations in the protein and nucleotide molecules of the invention may improve the production of fine chemicals, e.g., methionine, in an indirect fashion.
  • fine chemicals e.g., methionine
  • the regulatory mechanisms of metabolic pathways in the cell are necessarily intertwined, and the activation of one pathway may lead to the repression or activation of another in a concomitant fashion. Therefore, by modulating the activity of one or more of the proteins of the invention, the production or efficiency of activity of another fine chemical biosynthetic or degradative pathway may be impacted.
  • an MR protein may concomi- tantly derepress other amino acid biosynthetic pathways, since these pathways are interrelated.
  • the isolated nucleic acid sequences of the invention are con- tained within the genome of a Corynebacter um glutamicum strain available through the American Type Culture Collection, given designation ATCC 13032.
  • the nucleotide and amino acid sequences of RXA00655 are depicted in SEQ ID N0s:l, 18, 20, 22 and 2, 19, 21, 23 respectively, and the nucleotide and amino acid sequences of RXN02910 are depicted in SEQ ID NOs : 5 and 6, respectively.
  • SEQ ID NOs: 16 and 17 represent mutated RXN02910 nucleic acid and amino acid sequences, respectively.
  • the RXN02910 molecule depicted in SEQ ID NO: 16 contains a single nucleotide change from a guanine (G) to an adenine (A) at nucleotide residue 556 in the coding region, which results in a change from an aspartic acid (D) to an asparagine (N) at amino acid residue 186 of the encoded protein, set forth as SEQ ID NO: 17.
  • This polymorphism may cause modulation of regulation of methionine biosynthesis or other fine chemicals by RXN02910, e.g., decreased methionine biosynthesis .
  • the present invention also pertains to proteins which have an amino acid sequence which is substantially homologous to an amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 17, SEQ ID N0:19, SEQ ID NO:21, or SEQ ID NO:23.
  • a protein which has an amino acid sequence which is substantially homologous to a selected amino acid sequence is least about 50% homologous to the selected amino acid sequence, e . g. , the entire selected amino acid sequence.
  • a protein which has an amino acid sequence which is substantially homologous to a selected amino acid sequence can also be least about 50-60%, preferably at least about 60-70%, and more preferably at least about 70-80%, 80-90%, or 90-95%, and most preferably at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more homologous to the selected amino acid sequence.
  • the MR protein or a biologically active portion or fragment thereof of the invention can transcriptionally, translationally, or posttranslationally regulate a metabolic pathway in C. glu- ta- ⁇ uc ⁇ -- ⁇ !, e.g., the methionine metabolic pathway, or have one or more of the activities set forth herein.
  • the invention provides novel transgenic expression cassettes comprising in combination with a regulatory sequence a nucleic acid molecule coding for a metabolic pathway protein [ (MR) protein] or a fragment thereof, wherein said regulatory sequence is capable of mediating expression of said nucleic acid molecule.
  • said regulatory sequence is a promoter heterologous with regard to said nucleic acid molecule.
  • the regulatory sequence is a promoter sequence functional in Corynebacterium glutamicum.
  • MR proteins are capable of, for example, performing an enzymatic step involved in the transcriptional, translational, or posttranslational regulation of metabolic pathways in C. glutamicum.
  • Nucleic acid molecules encoding an MR protein are referred to herein as MR nucleic acid molecules.
  • the MR protein participates in the transcriptional, translational, or posttranslational regulation of one or more metabolic pathways .
  • the MR nucleic acid molecule is selected from the group consisting of:
  • nucleic acid molecule comprising a nucleotide sequence which is at least 60% identical to the nucleotide sequence of SEQ ID NO:l, SEQ ID NO : 5 , SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, or SEQ ID NO: 22, or a complement thereof;
  • nucleic acid molecule comprising a fragment of at least 30 nucleotides of a nucleic acid comprising the nucleotide sequence of SEQ ID NO:l, SEQ ID NO: 5, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, or SEQ ID NO: 22, or a complement thereof;
  • nucleic acid molecule which encodes a polypeptide comprising an amino acid sequence at least about 60% identical to the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 17, SEQ ID NO-.19, SEQ ID NO:21, or SEQ ID NO:23;
  • nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, or SEQ ID NO: 23, wherein the fragment comprises at least 10 contiguous amino acid residues of the amino acid sequence of SEQ ID NO: 2, SEQ ID NO:6, SEQ ID N0:17, SEQ ID NO.-19, SEQ ID NO:21, or SEQ ID NO: 23,
  • the transgenic expression cassette may comprise the nucleic acid molecule coding for the MR protein (e.g., RXA00655 or RXA02910) in antisense or sense orientation with regard to said promoter sequence .
  • the nucleic acid molecule coding for the MR protein encodes a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, or SEQ ID NO: 23.
  • said nucleic acid molecule comprises the nucleotide sequence set forth in SEQ ID NO:l, SEQ ID NO: 5, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, or SEQ ID NO: 22.
  • the nucleic acid molecule may also code for a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, or SEQ ID NO: 23.
  • nucleic acid molecule is intended to include DNA molecules (e.g., cDNA or genomic DNA) and RNA molecules (e.g., mRNA) and analogs of the DNA or RNA generated using nucleotide analogs. This term also encompasses untranslated sequence located at both the 3 ' and 5 ' ends of the coding region of the gene: at least about 100 nucleotides of sequence upstream from the 5' end of the coding region and at least about 20 nucleotides of sequence downstream from the 3 'end of the coding region of the gene.
  • the nucleic acid molecule can be single- stranded or double-stranded, but preferably is double-stranded DNA.
  • transgenic expression cassette is in- tended to include all kind of nucleic acids constructs obtained by methods of molecularbiology, wherein in said constructs either
  • the MR nucleic acid or part thereof e.g., a nucleic compris- ing the nucleotide sequence of SEQ ID NO:l, SEQ ID NO: 5, SEQ
  • a transgenic ex- pression construct may include the combination of an MR nucleic acid in combination with its natural promoter sequence, as long as this combination is isolated from its natural genomic context and/or placed in a different genomic context.
  • the promoter sequence is heterologous with regard to said MR nucleic acid.
  • Heterologous is intended to describe the combination of a MR nucleic acid with a promoter sequence, wherein said promoter sequence is naturally not regulating expression of the very same MR nucleic acid.
  • Transgenic with regard to a vector or a host organism intents to describe vector or host organisms which comprise a transgenic expression cassette as defined above.
  • An "isolated" nucleic acid molecule is one which is separated from other nucleic acid molecules which are present in the natu- ral source of the nucleic acid.
  • a nucleic acid molecule of the present invention e . g. , a nucleic acid molecule having a nucleotide sequence of SEQ ID N0:1, SEQ ID NO: 5, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, or SEQ ID NO: 22, or a portion thereof, can be isolated using standard molecular biology techniques and the sequence information provided herein.
  • a C. glutamicum MR DNA can be isolated from a C.
  • glutamicum library using all or portion of one of the sequences of SEQ ID N0:1, SEQ ID NO : 5 , SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, or SEQ ID NO: 22 as a hybridization probe and standard hybridization techniques (e . g. , as described in Sambrook, J., Fritsh, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual . 2nd, ed. , Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989) .
  • nucleic acid molecule encompassing all or a portion of one of the sequences of SEQ ID N0:1, SEQ ID NO : 5 , SEQ ID N0:16, SEQ ID N0:18, SEQ ID NO:20, or SEQ ID NO:22 can be isolated by the polymerase chain reaction using oligonucleotide primers designed based upon this sequence (e.g., a nucleic acid molecule encompassing all or a portion of one of the sequences of SEQ ID NO:l, SEQ ID NO: 5, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, or SEQ ID NO: 22 can be isolated by the polymerase chain reaction using oligonucleotide primers designed based upon this same sequence of SEQ ID NO:l, SEQ ID NO: 5, SEQ ID NO: 16, SEQ ID NO:18, SEQ ID NO:20, or SEQ ID NO:22).
  • mRNA can be isolated from normal bacterial cells (e.g., by the guanidinium- thiocyanate extraction procedure of Chirgwin et al . (1979) Biochemistry 18: 5294-5299) and DNA can be prepared using reverse transcriptase (e.g., Moloney MLV reverse transcriptase, available from Gibco/BRL, Bethesda, MD; or AMV reverse transcriptase, available from Seikagaku America, Inc., St. Russia, FL) .
  • reverse transcriptase e.g., Moloney MLV reverse transcriptase, available from Gibco/BRL, Bethesda, MD; or AMV reverse transcriptase, available from Seikagaku America, Inc., St. Russia, FL
  • Synthetic oligonucleotide primers for polymerase chain reaction amplification can be designed based upon one of the nucleotide sequences shown in SEQ ID NO:l, SEQ ID NO: 5, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO:20, or SEQ ID NO:22.
  • a nucleic acid of the invention can be amplified using cDNA or, alternatively, genomic DNA, as a template and appropriate oligonucleotide primers ac- cording to standard PCR amplification techniques.
  • the nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis.
  • oligonucleotides corresponding to an MR nucleotide sequence can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.
  • a transgenic expression cassette comprises one of the nucleotide sequences shown in SEQ ID NO:l, SEQ ID NO: 5, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, or SEQ ID NO: 22.
  • the sequences of SEQ ID NO:l, SEQ ID NO: 5, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, or SEQ ID NO: 22 correspond to the Corynebacterium glutamicum MR DNAs of the invention.
  • This DNA comprises sequences encoding MR proteins (i.e., the "coding region", indicated in each sequence in SEQ ID NO : 1 , SEQ ID NO: 5, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, or SEQ ID NO: 22), as well as 5' untranslated sequences and 3' untranslated sequences, also indicated in SEQ ID NO:l, SEQ ID NO: 5, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, or SEQ ID NO: 22.
  • the nucleic acid molecule can comprise only the coding region of any of the sequences in SEQ ID NO : 1 , SEQ ID NO: 5, SEQ ID NO: 16, SEQ ID NO:18, SEQ ID NO:20, or SEQ ID NO:22.
  • a transgenic expression cassette of the invention comprises a nucleic acid molecule which is a complement of one of the nucleotide sequences shown in SEQ ID NO:l, SEQ ID NO : 5 , SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, or SEQ ID NO: 22, or a portion thereof.
  • a nucleic acid molecule which is complementary to one of the nucleotide sequences shown in SEQ ID NO:l, SEQ ID NO: 5, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, or SEQ ID NO: 22 is one which is sufficiently complementary to one of the nucleotide sequences shown in SEQ ID NO:l, SEQ ID NO: 5, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, or SEQ ID NO: 22 such that it can hybridize to one of the nucleotide se- quences shown in SEQ ID NO:l, SEQ ID NO : 5 , SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, or SEQ ID NO: 22, thereby forming a stable duplex.
  • a transgenic expression cassette of the invention comprises a nucleotide sequence which is at least about 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60%, preferably at least about 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, or 70%, more preferably at least about 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, or 80%, 81%, 82%, 83%,
  • a transgenic expression cassette of the invention comprises a nucleotide sequence which hybridizes, e.g., hybridizes under stringent conditions, to one of the nucleotide sequences shown in SEQ ID N0:1, SEQ ID NO: 5, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, or SEQ ID NO: 22, or a portion thereof.
  • the transgenic expression cassette of the invention can comprise only a portion of the coding region of one of the sequences in SEQ ID N0:1, SEQ ID NO : 5 , SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, or SEQ ID NO: 22, for example a fragment which can be used as a probe or primer or a fragment encoding a biologically active portion of an MR protein.
  • the nucleotide sequences determined from the cloning of the MR genes from C. glutamicum allows for the generation of probes and primers designed for use in identifying and/or cloning MR homo- logues in other cell types and organisms, as well as MR homo- logues from other Corynebac teria or related species.
  • the probe/primer typically comprises substantially purified oligonu- cleotide.
  • the oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, preferably about 25, more preferably about 40, 50 or 75 consecutive nucleotides of a sense strand of one of the sequences set forth in SEQ ID NO:l, SEQ ID NO: 5, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, or SEQ ID NO: 22, an anti- sense sequence of one of the sequences set forth in SEQ ID NO:l, SEQ ID NO: 5, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, or SEQ ID NO: 22, or naturally occurring mutants thereof.
  • Primers based on a nucleotide sequence of SEQ ID NO:l, SEQ ID NO: 5, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, or SEQ ID NO: 22 can be used in PCR reactions to clone MR homologues .
  • Probes based on the MR nucleotide sequences can be used to detect transcripts or genomic se- quences encoding the same or homologous proteins.
  • the probe further comprises a label group attached thereto, e . g. the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor.
  • Such probes can be used as a part of a diagnostic test kit for identifying cells which misexpress an MR protein, such as by measuring a level of an MR-encoding nucleic acid in a sample of cells, e.g., detecting MR mRNA levels or determining whether a genomic MR gene has been mutated or deleted.
  • the transgenic expression cassette comprises a nucleic acid molecule encoding a protein or portion thereof which includes an amino acid sequence which is sufficiently homologous to an amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, or SEQ ID NO: 23 such that the protein or portion thereof maintains the ability to transcriptionally, translationally, or posttranslationally regulate a metabolic pathway in C. glutamicum.
  • the language "sufficiently homologous” refers to proteins or portions thereof which have amino acid sequences which include a minimum number of identical or equivalent (e . g. , an amino acid residue which has a similar side chain as an amino acid residue in one of the sequences of SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, or SEQ ID NO: 23) amino acid residues to an amino acid sequence of SEQ ID NO : 2 ,
  • SEQ ID NO: 6, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, or SEQ ID NO: 23 such that the protein or portion thereof is able to transcriptionally, translationally, or posttranslationally regulate a metabolic pathway, e.g., methionine biosynthesis, in C. glu- tamicu-n.
  • a metabolic pathway e.g., methionine biosynthesis
  • Protein members of such metabolic pathways, as described herein may function to regulate the biosynthesis or degradation of one or more fine chemicals. Examples of such activities are also described herein.
  • “the function of an MR protein” contributes to the overall regulation of one or more fine chemical metabolic pathway, or contributes, either directly or indirectly, to the yield, production, and/or efficiency of production of one or more fine chemicals e . g. , methionine.
  • the protein is at least about 50-60%, preferably at least about 60-70%, and more preferably at least about 70-80%, 80-90%, 90-95%, and most preferably at least about 96%, 97%, 98%, 99% or more homologous to an entire amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, or SEQ ID NO: 23.
  • homologous MR proteins preferably homologous RXA00655 or RXN02910 proteins may be derived from other mi- croorganisms, preferably from procaryotic microorganisms.
  • Procaryotic microorganism is intended to include gram-positive and gram-negative bacteria.
  • ther term includes all genera and species of the Enterobacteriaceae or No- cardiaceae family, e.g. the Enterobacteriaceae species Es- cherichia, Serratia, Proteus, Enterobacter , Klebsiella, Salmonella, Shigella, Edwardsielle, Citrobacter, Morganella, Providencia and Yersinia.
  • Pseudomonas Burkholderia, Nocardia, Acetobacter, Streptomyces, Gluconobac- ter, Corynebacterium, Brevibacterium, Bacillus, Clostridium,
  • Corynebacterium and Streptomyces species like e.g., the Corynebacterium species exemplified in Table 1, Corynebacterium diphtheriae, Corynebac- terium efficiens and Streptomyces_coelicolor .
  • Examples for homologous MR proteins may include:
  • RXN02910 is intended to describe polypeptides encoded by a nucleic acid molecule comprising a nucleic acid molecule selected from the group consisting of:
  • nucleic acid molecule comprising a nucleotide sequence which is at least 60% identical to the nucleotide sequence of SEQ ID NO: 1
  • nucleic acid molecule comprising a fragment of at least 30 nucleotides of a nucleic acid comprising the nucleotide se- quence of SEQ ID NO: 5 or 16;
  • nucleic acid molecule which encodes a polypeptide comprising an amino acid sequence at least about 60% identical to the amino acid sequence of SEQ ID NO: 6 or 17 and
  • nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO: 6 wherein the fragment comprises at least 10 contiguous amino acid residues of the amino acid sequence of SEQ ID NO : 6 or 17.
  • RXA00655 is intended to describe polypeptides encoded by a nucleic acid molecule comprising a nucleic acid molecule selected from the group consisting of:
  • nucleic acid molecule comprising a nucleotide sequence which is at least 60% identical to the nucleotide sequence of SEQ ID N0:1, 18, 20 or 22;
  • nucleic acid molecule comprising a fragment of at least 30 nucleotides of a nucleic acid comprising the nucleotide sequence of SEQ ID NO : 1, 18, 20 or 22;
  • nucleic acid molecule which encodes a polypeptide comprising an amino acid sequence at least about 60% identical to the amino acid sequence of SEQ ID NO : 2 , 19, 21 or 23;
  • nucleic acid molecule which encodes a fragment of a poly- peptide comprising the amino acid sequence of SEQ ID NO : 2 , 19, 21 or 23 wherein the fragment comprises at least 10 contiguous amino acid residues of the amino acid sequence of SEQ ID NO: 2, 19, 21 or 23,
  • Portions of proteins encoded by the MR nucleic acid molecules of the invention are preferably biologically active portions of one of the MR proteins.
  • biologically active portion of an MR protein is intended to include a portion, e . g. , a domain/motif, of an MR protein that transcriptionally, translationally, or posttranslationally regulates a metabolic pathway in C. glutamicum, or has an activity as set forth herein.
  • an assay of enzymatic activity may be performed. Such assay methods are well known to those of ordinary skill in the art, as detailed in Example 8 of the Exemplification.
  • Additional nucleic acid fragments encoding biologically active portions of an MR protein can be prepared by isolating a portion of one of the sequences in SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, or SEQ ID NO: 23, SEQ ID NO: 19, SEQ ID NO: 21, or SEQ ID NO: 23 expressing the encoded por- tion of the MR protein or peptide ( e . g. , by recombinant expression in vi tro) and assessing the activity of the encoded portion of the MR protein or peptide.
  • the invention further encompasses nucleic acid molecules that differ from one of the nucleotide sequences shown in SEQ ID NOs:
  • SEQ ID NO:l SEQ ID NO : 5 , SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, or SEQ ID NO: 22, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22 (and portions thereof) due to degeneracy of the genetic code and thus encode the same MR protein as that encoded by the nucleotide se- quences shown in SEQ ID NO:l, SEQ ID NO: 5, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, or SEQ ID NO: 22, SEQ ID NO: 18, SEQ ID NO: 20, or SEQ ID NO: 22.
  • an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino acid sequence shown in SEQ ID NO: 2, SEQ ID NO : 6 , SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, or SEQ ID NO: 23, SEQ ID NO: 19, SEQ ID NO: 21, or SEQ ID NO: 23.
  • the nucleic acid molecule of the invention encodes a full length C.
  • glu -amicum protein which is substantially homologous to an amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 17, ' SEQ ID NO: 19, SEQ ID NO: 21, or SEQ ID NO: 23, SEQ ID NO: 19, SEQ ID NO: 21, or SEQ ID NO: 23 (encoded by an open reading frame shown in SEQ ID NO:l, SEQ ID NO: 5, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, or SEQ ID NO: 22, SEQ ID NO: 18, SEQ ID NO: 20, or SEQ ID NO: 22) .
  • the invention includes nucleotide and amino acid sequences having a percent identity to a nucleotide or amino acid sequence of the invention which is greater than that of a sequence of the prior art (e.g., a Genbank sequence (or the protein encoded by such a sequence) .
  • a sequence of the prior art e.g., a Genbank sequence (or the protein encoded by such a sequence)
  • One of ordinary skill in the art would be able to calculate the lower threshold of percent identity for any given sequence of the invention by examin- ing the GAP-calculated percent identity scores for each of the three top hits for a given sequence, and by subtracting the highest GAP-calculated percent identity from 100 percent.
  • nucleic acid and amino acid sequences having percent identities greater than the lower threshold so calculated are also encompassed by the invention.
  • the terms “gene” and “recombinant gene” refer to nucleic acid molecules comprising an open reading frame encoding an MR protein, pref- erably a C. glutamicum MR protein. Such natural variations can typically result in 1-5% variance in the nucleotide sequence of the MR gene. Any and all such nucleotide variations and resulting amino acid polymorphisms in MR that are the result of natu- ral variation and that do not alter the functional activity of MR proteins are intended to be within the scope of the invention.
  • Nucleic acid molecules corresponding to natural variants and non-C. glutamicum homologues of the C. glutamicum MR DNA of the invention can be isolated based on their homology to the C. glutamicum MR nucleic acid disclosed herein using the C. glutamicum DNA, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions.
  • an isolated nucleic acid molecule of the invention is at least 15 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising a nucleotide sequence of SEQ ID N0:1, SEQ ID NO : 5 , SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, or SEQ ID NO: 22, SEQ ID NO: 18, SEQ ID NO: 20, or SEQ ID NO: 22.
  • the nucleic acid is at least 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 225 or more nucleotides in length.
  • hybridizes under stringent conditions is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% homologous to each other typically remain hybridized to each other.
  • the conditions are such that sequences at least about 65%, more preferably at least about 70%, and even more preferably at least about 75% or more homologous to each other typically remain hybridized to each other.
  • stringent conditions are known to those of ordinary skill in the art and can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989) , 6.3.1-6.3.6.
  • a preferred, non-limiting example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50-65°C.
  • SSC 6X sodium chloride/sodium citrate
  • an isolated nucleic acid molecule of the invention that hybridizes un- der stringent conditions to a sequence of SEQ ID N0:1, SEQ ID
  • SEQ ID NO: 5 corresponds to a naturally-occurring nucleic acid molecule.
  • a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein).
  • the nucleic acid encodes a natural C. glutamicum MR protein.
  • nucleotide substitutions leading to amino acid substi- tutions at "non-essential" amino acid residues can be made in a sequence of SEQ ID NO:l, SEQ ID NO: 5, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, or SEQ ID NO: 22, SEQ ID NO: 18, SEQ ID NO: 20, or SEQ ID NO: 22.
  • a "non-essential" amino acid residue is a residue that can be altered from the wild-type sequence of one of the MR proteins (SEQ ID NO : 2 , SEQ ID NO: 6, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, or SEQ ID NO: 23, SEQ ID NO: 19, SEQ ID NO: 21, or SEQ ID NO: 23) without altering the activity of said MR protein, whereas an "essential" amino acid residue is required for MR protein activity.
  • Other amino acid residues may not be essential for activity and thus are likely to be amenable to alteration without altering MR activity.
  • nucleic acid molecules encoding MR proteins that contain changes in amino acid residues that are not essential for MR activity.
  • Such MR proteins differ in amino acid sequence from a sequence contained in SEQ ID NO : 2 , SEQ ID NO: 6, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, or SEQ ID NO: 23, SEQ ID NO: 19, SEQ ID NO: 21, or SEQ ID NO: 23 yet retain at least one of the MR activities described herein.
  • the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about 50% homologous to an amino acid sequence of SEQ ID NO: 2,
  • SEQ ID NO: 6 SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, or SEQ ID NO: 23 and is capable of transcriptionally, translationally, or posttranslationally regulating a metabolic pathway in C. glutamicum, or has one or more activities set forth herein.
  • the protein encoded by the nucleic acid molecule is at least about 50-60% homologous to one of the sequences in SEQ ID NO: 2, SEQ ID NO : 6 , SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, or SEQ ID NO: 23, more preferably at least about 60-70% homologous to one of the sequences in SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, or SEQ ID NO: 23, even more preferably at least about 70-80%, 80-90% homologous to one of the sequences in SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, or SEQ ID NO: 23, and most preferably at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% homologous to one of the sequences in SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 23, more preferably at
  • sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of one protein or nucleic acid for optimal alignment with the other protein or nucleic acid) .
  • the amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in one sequence ( e . g.
  • one of the sequences of SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, or SEQ ID NO: 23 is occupied by the same amino acid residue or nucleotide as the corresponding position in the other sequence (e.g., a mutant form of the sequence selected from SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, or SEQ ID NO: 23), then the molecules are homologous at that position (i.e., as used herein amino acid or nucleic acid "homology” is equivalent to amino acid or nucleic acid "identity") .
  • An isolated nucleic acid molecule encoding an MR protein homologous to a protein sequence of SEQ ID NO : 2 , SEQ ID NO: 6, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, or SEQ ID NO: 23 can be cre- ated by introducing one or more nucleotide substitutions, additions or deletions into a nucleotide sequence of SEQ ID NO:l, SEQ ID NO: 5, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, or SEQ ID NO: 22 such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein ' .
  • Mutations can be introduced into one of the sequences of SEQ ID NO:l, SEQ ID NO: 5, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, or SEQ ID NO: 22 by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis.
  • conservative amino acid substitutions are made at one or more predicted non- essential amino acid residues.
  • a "conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art.
  • amino acids with basic side chains e.g., lysine, arginine, histidine
  • acidic side chains e.g., aspartic acid, glutamic acid
  • uncharged polar side chains e . g.
  • glycine asparagine, glutamine, serine, threonine, tyrosine, cysteine
  • nonpolar side chains e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan
  • beta-branched side chains e.g., threonine, valine, isoleucine
  • aromatic side chains e.g., tyrosine, phenylalanine, tryptophan, histidine.
  • a pre- dieted nonessential amino acid residue in an MR protein is preferably replaced with another amino acid residue from the same side chain family.
  • mutations can be introduced randomly along all or part of an MR coding sequence, such as by saturation mutagenesis, and the resul- tant mutants can be screened for an MR activity described herein to identify mutants that retain MR activity.
  • the encoded protein can be expressed recombinantly and the activity of the protein can be determined using, for example, assays described herein (see Example 6 of the Exemplification) .
  • the invention also provides MR chimeric or fusion proteins.
  • an MR “chimeric protein” or “fusion protein” com- prises an MR polypeptide operatively linked to a non-MR polypeptide.
  • An "MR polypeptide” refers to a polypeptide having an amino acid sequence corresponding to an MR protein
  • a non-MR polypeptide refers to a polypeptide having an amino acid sequence corresponding to a protein which is not substan- tially homologous to the MR protein, e . g. , a protein which is different from the MR protein and which is derived from the same or a different organism.
  • the term "operatively linked" is intended to indicate that the MR polypeptide and the non-MR polypeptide are fused in-frame to each other.
  • the non-MR polypeptide can be fused to the N-terminus or C-terminus of the MR polypeptide.
  • the fusion protein is a GST-MR fusion protein in which the MR sequences are fused to the C-terminus of the GST sequences.
  • Such fusion proteins can facilitate the purification of recombinant MR proteins.
  • the fusion protein is an MR protein containing a heterologous signal sequence at its N- terminus . In certain host cells (e. g. , mammalian host cells), expression and/or secretion of an MR protein can be increased through use of a heterologous signal sequence.
  • an MR chimeric or fusion protein of the invention is produced by standard recombinant DNA techniques.
  • DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, for example by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appro- priate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation.
  • the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers.
  • PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and reampli- fied to generate a chimeric gene sequence (see, for example, Current Protocols in Molecular Biology, eds. Ausubel et al . John Wiley & Sons: 1992).
  • anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and reampli- fied to generate a chimeric gene sequence
  • many expression vectors are com-bitally available that already encode a fusion moiety (e . g. , a GST polypeptide) .
  • An MR-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the MR protein.
  • Homologues of the MR protein can be generated by mutagenesis, e.g., discrete point mutation or truncation of the MR protein.
  • the term "homologue” refers to a variant form of the MR protein which acts as an agonist or antagonist of the activity of the MR protein.
  • An agonist of the MR protein can re- tain substantially the same, or a subset, of the biological activities of the MR protein.
  • An antagonist of the MR protein can inhibit one or more of the activities of the naturally occurring form of the MR protein, by, for example, competitively binding to a downstream or upstream member of the MR regulatory cascade which includes the MR protein.
  • the C the C.
  • glutamicum MR protein and homologues thereof of the present invention may modulate the activity of one or more metabolic pathways which MR proteins regulate in this microorganism.
  • homologues of the MR protein can be identified by screening combinatorial libraries of mutants, e.g., truncation mutants, of the MR protein for MR protein ago- nist or antagonist activity.
  • a variegated library of MR variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library.
  • a variegated library of MR variants can be produced by, for example, enzymatically ligating a mixture of synthetic oli- gonucleotides into gene sequences such that a degenerate set of potential MR sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins ( e . g. , for phage display) containing the set of MR sequences therein.
  • fusion proteins e . g. , for phage display
  • libraries of fragments of the MR protein coding can be used to generate a variegated population of MR fragments for screening and subsequent selection of homologues of an MR pro- tein.
  • a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of an MR coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA which can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with SI nuclease, and ligating the resulting fragment library into an expression vector.
  • an expression library can be derived which encodes N-terminal, C- terminal and internal fragments of various sizes of the MR protein.
  • Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of MR homologues.
  • the most widely used techniques, which are amenable to high through-put analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected.
  • Recursive ensemble mutagenesis (REM) a new technique which enhances the frequency of func- tional mutants in the libraries, can be used in combination with the screening assays to identify MR homologues (Arkin and Your- van (1992) PNAS 89 . - 7811-7815 ; Delgrave et al . (1993) Protein Engineering 6(3) :327-331) .
  • cell based assays can be exploited to analyze a variegated MR library, using methods well known in the art.
  • an antisense nucleic acid comprises a nucleotide sequence which is complementary to a "sense" nucleic acid encoding a protein, e. g. , complementary to the coding strand of a double-stranded DNA molecule or complementary to an mRNA sequence. Accordingly, an antisense nucleic acid can hydrogen bond to a sense nucleic acid.
  • the antisense nucleic acid can be complementary to an entire MR coding strand, or to only a portion thereof.
  • an antisense nucleic acid molecule is antisense to a "coding region" of the coding strand of a nucleotide sequence encoding an MR protein.
  • coding region refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues.
  • the antisense nucleic acid molecule is antisense to a "noncoding re- gion" of the coding strand of a nucleotide sequence encoding MR.
  • noncoding region refers to 5' and 3 1 sequences which flank the coding region that are not translated into amino acids (i.e., also referred to as 5' and 3' untranslated regions).
  • antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick base pairing.
  • the antisense nucleic acid molecule can be complementary to the entire coding region of MR mRNA, but more preferably is an oligonucleotide which is antisense to only a portion of the coding or non- coding region of MR mRNA.
  • the antisense oligonucleotide can be complementary to the region surrounding the translation start site of MR mRNA.
  • An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length.
  • An antisense nucleic acid of the in- vention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art.
  • an antisense nucleic acid e.g., an antisense oligonucleotide
  • an antisense nucleic acid can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids.
  • the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection) .
  • Another aspect of the invention pertains to vectors, preferably expression vectors, containing at least one transgenic expression cassette of the invention comprising a nucleic acid encoding an MR protein (or a portion thereof) .
  • vector refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.
  • plasmid refers to a circular double stranded DNA loop into which additional DNA segments can be ligated.
  • viral vec- tor refers to a viral vec- tor, wherein additional DNA segments can be ligated into the viral genome.
  • Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication) . Other vectors are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome.
  • vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "expression vectors".
  • expression vectors of utility in recombinant DNA techniques are often in the form of plasmids .
  • plasmid and vector can be used interchangeably as the plasmid is the most commonly used form of vector.
  • the invention is intended to include such other forms of expression vectors, such as phage vectors which serve equivalent functions .
  • transgenic expression vectors of the invention comprise a transgenic expression cassette of the invention in a form suitable for expression of the MR nucleic acid in a host cell.
  • the transgenic expression cassette includes one or more regulatory sequences (promoters) , selected on the basis of the host cells to be used for expression, which is operatively linked to the nucleic acid sequence to be expressed.
  • "operably linked” is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence (s) in a manner which allows for expression of the nu- cleotide sequence (e.g., in an in vi tro transcription/translation system or in a host cell when the vector is introduced into the host cell) .
  • regulatory sequence is intended to include promoters, enhancers and other expression control elements (e . g. , polyade- nylation signals) .
  • Such regulatory sequences are described, for example, in Goeddel; Gene Expression Technology: Methods in En- zymology 185, Academic Press, San Diego, CA (1990) and in Vasi- cova P. Patek M. Nesvera J. Sahm H. Eikmanns B. Journal of Bac- teriology (1999) 181 (19) : 6188-91, in Patek M. et al . (1996) Mi crobiology 142:1297-309, and in Mateos et al .
  • regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cell and those which direct expression of the nucleotide sequence only in certain host cells.
  • Preferred regulatory sequences are, for example, promoters such as cos-, tac-, trp-, tet-, trp-tet-, lpp-, lac-, lpp-lac-, lacl"-, T7-, T5-, T3-, gal-, trc-, ara- , SP6-, arny, SP02 , ⁇ -P R - or ⁇ -P L , which are used preferably in bacteria.
  • the expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., MR proteins, mutant forms of MR proteins, fusion proteins, etc.).
  • the transgenic expression cassettes or expression vectors of the invention can be designed for expression of MR proteins in prokaryotic or eukaryotic cells.
  • MR genes can be ex- pressed in bacterial cells such as C. gl u tamicum, insect cells (using baculovirus expression vectors) , yeast and other fungal cells, algae and multicellular plant cells, or mammalian cells. Suitable host cells are discussed further in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990) .
  • the transgenic expression cassette or expression vector can be transcribed and translated in vi tro, for example using T7 promoter regulatory sequences and T7 polymerase.
  • Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein.
  • Typical fusion expression vectors may fuse glutathione S- transferase (GST) , maltose E binding protein, or protein A, respectively, to the target recombinant protein.
  • GST glutathione S- transferase
  • suitable inducible E. coli expression vectors include pTrc (Amann et al . , (1988) Gene 69:301-315) pLG338, pA- CYC184, pBR322, pUC18, pUC19, pKC30, pRep4, pHSl, pHS2 , pPLc236, PMBL24, pLG200, pUR290, pIN-III113-Bl, ⁇ gtll, pBdCl , and pET lid (Studier et al . , Gene Expression Technology: Methods in Enzymol - ogy 185, Academic Press, San Diego, California (1990) 60-89; and Pouwels et al .
  • E. coli C. glutamicum shuttle expression vectors can be found in Eikmanns B.J., et al . (1991) Gene 102:93-8.
  • Suitable cloning vectors for use in Corynebacterium glu tamicum are for example those disclosed in Sinskey et al . , U.S. Patent No. 4,649,119, and techniques for genetic manipulation of C. glutamicum and the related Brevi-bacterium species (e.g., lactofermentum) (Yoshihama et al , J. Bacteriol .
  • Target gene expression from the pTrc vector relies on host RNA polymerase transcription from a hybrid trp-lac fusion promoter.
  • appropriate vectors may be selected.
  • the plasmids pIJlOl, pIJ364, pIJ702 and pIJ361 are known to be useful in transforming Streptomyces, while plasmids pUBllO, pC194, or pBD214 are suited for transformation of Bacillus species.
  • nucleic acid sequence of the nucleic acid is altered so that the individual codons for each amino acid are those preferentially utilized in the bacterium chosen for expression, such as C. glutamicum (Wada et al . (1992) Nucleic Acids Res . 20:2111-2118) .
  • Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.
  • transgenic host cells into which a transgenic expression cassette or expression vector of the invention has been introduced.
  • the terms "host cell” and “transgenic host cell” are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the 'scope of the term as used herein.
  • a host cell can be any prokaryotic or eukaryotic cell.
  • an MR -protein can be expressed in bacterial cells such as C. glutamicum, insect cells, yeast or mammalian cells.
  • Other suitable host cells are known to one of ordinary skill in the art.
  • Microorganisms related to Corynebacterium glutamicum which may be conveniently used as host cells for the nucleic acid and protein molecules of the invention are set forth in Table 1.
  • Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques.
  • transformation and "trans- fection” are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., linear DNA or RNA (e.g., a linearized vector or a gene construct alone without a vector) or nucleic acid in the form of a vector (e.g., a plasmid, phage, phasmid, phagemid, transposon or other DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, li- pofection, or electroporation.
  • foreign nucleic acid e.g., linear DNA or RNA (e.g., a linearized vector or a gene construct alone without a vector) or nucleic acid in the form of a vector (e.g., a plasmid, phage,
  • Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al . (Molecular Cloning : A Laboratory Manual . 2nd, ed. , Cold Spring Har- bor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989), and other laboratory manuals.
  • a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest.
  • selectable markers include those which confer resistance to drugs, such as kanamycin, tetracyclin, bleomycin, chlorampheni- col, lincomycin.
  • Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encod- ing an MR protein or can be introduced on a separate vector.
  • Cells transformed with the introduced nucleic acid can be identified by, for example, drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die) .
  • antibiotic resistence genes that can be used in C. glutamicum can be found in: Tauch A. Puhler A. Kalinowski J.
  • transgenic host organisms preferably microorganisms
  • transgenic host organisms which contain selected systems which allow for regulated expression of the introduced gene.
  • inclusion of an MR gene on a vector placing it under control of the lac operon permits expression of the MR gene only in the presence of IPTG.
  • Such regulatory systems are well known in the art and are described in e.g., Eikmanns B.J. et al. (1991) Gene 102:93-8.
  • a host cell of the invention such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (i.e., express) an MR protein.
  • the invention further provides methods for producing MR proteins using the host cells of the invention.
  • the method comprises culturing the host cell of invention (into which a transgenic expression cassette or expression vector encoding an MR protein has been introduced, or into which genome has been introduced a gene encoding a wild-type or altered MR protein) in a suitable medium until MR protein is produced.
  • the method further comprises isolating MR proteins from the medium or the host cell.
  • Said methods may include one or more of the methods selected from the following group of methods consisting of:
  • MR protein e.g., negative regulatory protein
  • MR protein e.g., negative regulatory protein
  • MR protein e.g., negative regulatory protein
  • an endogenous MR gene in a host cell is disrupted (e.g., by homologous recombination or other genetic means known in the art) such that expression of its protein product does not occur.
  • an endogenous or introduced MR gene in a host cell has been altered by one or more point mutations, deletions, or inversions.
  • Said ' MR gene may still encodes a functional MR protein but may also encode a non- funtional MR protein or a MR protein with modified (e.g., increased or decreased) actrivity.
  • one or more of the regulatory regions (e.g., a promoter, repres- sor, or inducer) of an MR gene in a microorganism has been altered (e . g. , by deletion, truncation, inversion, or point mutation) such that the expression of the MR gene is modulated.
  • a promoter, repres- sor, or inducer e.g., by deletion, truncation, inversion, or point mutation
  • host cells containing more than one of the described MR gene and protein modifications may be readily produced using the methods of the invention, and are meant to be included in the present invention.
  • a vector which contains at least a portion of an MR gene into which a deletion, addition or substitution has been introduced to thereby alter, e.g., functionally disrupt, the MR gene.
  • this MR gene is a Corynebacterium glutamicum MR gene, but it can be a homologue from a related bacterium or even from a mammalian, yeast, or insect source.
  • the vector is designed such that, upon homologous recombination, the endogenous MR gene is functionally disrupted (i.e., no longer encodes a functional protein; also referred to as a "knock out" vector) .
  • the vector can be designed such that, upon homologous recombination, the endogenous MR gene is mutated or otherwise altered (e.g., the upstream regulatory region can be altered to thereby alter the expression of the endogenous MR protein) .
  • the altered portion of the MR gene is flanked at its 5' and 3' ends by additional nucleic acid of the MR gene to allow for homologous recombination to occur between the exogenous MR gene carried by the vector and an endogenous MR gene in a microorganism.
  • the additional flanking MR nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene.
  • flanking DNA should have lengths between lOObasepairs and a few kilobases (both at the 5' and 3' ends) are included in the vector (see e . g. , Thomas, K.R., and Capecchi, M.R. (1987) Cell 51: 503 for a description of homolo- gous recombination vectors) .
  • another selection can be used to construct chromosomal recombinations in which the selection marker is retrieved by a method of postive selection Schafer A. Tauch A. Jager W. Kalinowski J. Thierbach G. Puhler A. Gene. 145 (1) : 69-73 , 1994. .
  • the vector is introduced into a microorganism ( e. g. , by electropora- tion) and cells in which the introduced MR gene has homologously recombined with the endogenous MR gene are selected, using art- known techniques .
  • a decrease in expression of a MR protein may be achieved by expressing antisense RNA directed against the MR encoding mRNA.
  • Said antisense RNA is described above.
  • Methods for regulation of gene expression using antisense genes are well known to the person skilled in the art (see e.g., Weintraub, H. et al . , Antisense RNA as a molecular tool for genetic analysis, Reviews - Trends in Genetics, Vol. 1(1) 1986).
  • the antisense nucleic acid molecules of the invention are typically administered to a cell or generated in si tu such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding an MR protein to thereby inhibit expression of the protein, e . g. , by inhibiting transcription and/or translation.
  • the hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule which binds to DNA duplexes, through specific interactions in the major groove of the double helix.
  • the antisense molecule can be modified such that it specifically binds to a receptor or an antigen expressed on a selected cell surface, e . g.
  • the antisense nucleic acid molecule by link- ing the antisense nucleic acid molecule to a peptide or an antibody which binds to a cell surface receptor or antigen.
  • the antisense nucleic acid molecule can also be delivered to cells using the vectors described herein.
  • vector con- structs in which the antisense nucleic acid molecule is placed under the control of a strong prokaryotic, viral, or eukaryotic promoter are preferred.
  • the antisense nucleic acid molecule of the invention is an ⁇ -anomeric nucleic acid molecule.
  • An ⁇ - anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual ⁇ -units, the strands run parallel to each other (Gaultier et al . (1987) Nucleic Acids . Res . 15:6625-6641).
  • the antisense nucleic acid molecule can also comprise a 2 ' -o-methylribonucleotide
  • an antisense nucleic acid of the invention is a ribozyme.
  • Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region.
  • ribozymes e.g., hammerhead ribozymes (described in Haselhoff and Gerlach (1988) Nature 334:585-591)) can be used to catalytically cleave MR mRNA transcripts to thereby inhibit translation of MR mRNA.
  • a ribozyme having specificity for an MR-encoding nucleic acid can be designed based upon the nucleotide sequence of an MR DNA disclosed herein (i.e., SEQ ID N0:1, SEQ ID NO: 5, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO:20, or SEQ ID NO:22).
  • SEQ ID N0:1, SEQ ID NO: 5, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO:20, or SEQ ID NO:22 i.e., SEQ ID N0:1, SEQ ID NO: 5, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO:20, or SEQ ID NO:22.
  • a derivative of a Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in an MR-encoding mRNA. See, e.g., Cech et al .
  • MR mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel, D. and Szostak, J.W. (1993) Science 261:1411-1418.
  • MR gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of an MR nucleotide sequence (e.g., an MR promoter and/or enhancers) to form triple helical structures that prevent transcription of an MR gene in target cells. See generally, Helene, C.
  • nucleotide sequences complementary to the regulatory region of an MR nucleotide sequence e.g., an MR promoter and/or enhancers
  • additional or alternative methods known to the person skilled in the art can be used to modulate, e . g. , suppress or increase, expression from a gene (e . g. , a gene coding for a negative regulator of methionine biosynthesis) or to modulate, e.g., increase or suppress or inhibit activity of the corresponding gene product.
  • One method which may be used is the expression of a dominant- negative variant of the gene product (e . g. , a gene coding for a negative regulator of methionine biosynthesis) to suppress activity of, e.g., a negative regulator of methionine biosynthesis .
  • a dominant- negative variant of the gene product e . g. , a gene coding for a negative regulator of methionine biosynthesis
  • a negative regulator of methionine biosynthesis (e . g. , RXA00655 as exemplified by SEQ ID N0:1, 18, 20 or 22) is preferably a transcriptional regulator.
  • Transcriptional regulators are known to exists as dimers which bind to opposite parts of the DNA to struc- tures that might contain repeating sequences in so called dyad symmetry. The activity of DNA binding is determined within the amino acid sequence of the transcriptional regulator . Examples of the structural basis of the dimeric binding of such transcriptional regulators can be found in Schumacher M.A. and Brennan R.G. (2002) Molecular Microbiology. 45:885-93.
  • expression of different alleles of the same protein in one cell by producing hetero- dimeric proteins consisting of an unmutated and of a mutated allele of a regulatory protein confer a dominant negative phenotype for such an organism.
  • Examples of methods for constructing a mutant dominant negative repressor protein in organisms also expressing unmutated alleles of the same gene can be found in Journal of Molecular Biology (2002) 322 (2) : 311-24, and in Journal of Biological Chemistry (1994). 269 (11) : 8246-54.
  • the DNA-binding domain of said negative regulator of methionine biosynthesis may be inactivated.
  • mRNA stabilisation and destabi- lisation can be used as a method to either increase or decrease the life time of a given mRNA molecule.
  • Methods to influence the life time of a given mRNA can be found in Smolke CD. and Keasling J.D. (2002) Biotechnology & Bioengineering. 78 (4) : 412-24 , in Smolke CD. et al . (2001) Metabolic Engineering 3(4):313-21, and in Carrier T.A. and Keasling J.D. (1999) Biotechnology Progress 15(1) :58- 64.
  • nother method which may be used to modulate expression of a gene includes expression of DNA-binding proteins increasing or blocking or reducing expression from the gene, e . g. , a gene coding for a regulatory protein of methionine biosynthesis.
  • Blocking or reducing expression from the gene can be realized by utilizing specific DNA-binding proteins, e. g. , of the zinc-finger protein class of transcription factors. Said factors may be directed to . g. , regulatory regions of the gene to be suppressed. Utilization of said factors allows suppression of expression without altering the corresponding gene sequence. Methods are known to the person skilled in the art to construct artificial DNA- binding factors capable of binding to a specific target sequence. Increasing gene expression, e. g.
  • coding for a positive regulator of methionine biosynthesis can be realized by using the above described artificial DNA-binding factors by fusing them to a tran- scription activation domain, thereby creating an artificial initiator of transcription.
  • Protein-binding factors suitable for binding regulators of methionine biosynthesis and thereby suppressing activity may be based on R ⁇ A such as, e . g. aptamers (Famulok M und Mayer G (1999) Curr Top Microbiol Immunol 243:123-36), antibodies, antibody fragments, or single-chain antibodies. Methods for construction and utilization of these protein-binding factors are known to the person skilled in the art .
  • nucleic acid molecules, proteins, protein homologues, fusion proteins, primers, transgenic expression cassettes, expression vectors, and host cells described herein can be used in one or more of the following methods: modulation of cellular production of a desired compound, such as a fine chemical, e.g., methionine; identification of C. glutamicum and related organisms; mapping of genomes of organisms related to C. glu amicum; identification and localization of C. glutamicum sequences of interest; evolutionary studies; determination of MR protein regions required for function; modulation of an MR protein activity; and modulation of the activity of one or more metabolic pathways.
  • a desired compound such as a fine chemical, e.g., methionine
  • identification of C. glutamicum and related organisms identification of genomes of organisms related to C. glu amicum
  • identification and localization of C. glutamicum sequences of interest identification and localization of C. glutamicum sequences of interest
  • evolutionary studies determination of MR protein regions required for function
  • the MR nucleic acid molecules of the invention have a variety of uses. Manipulation of the MR nucleic acid molecules of the invention, e.g., suppressing or increasing expression or activity of the nucleic acid or protein molecules, respectively, results in the modulation of methionine biosynthesis. For example, a Corynebacterium glutamicum strain which overexpresses or has in- creased expression of RXN02910, a positive regulator of methio- ine biosynthesis, displays a significant increase in the production of methionine or other compounds of the methionine biosynthetic pathway.
  • Corynebacterium glu tamicum strain which is deficient in or has suppressed expression of RXN00655, a negative regulator of methioine biosynthesis, also displays a significant increase in the production of methionine or other compounds of the methionine biosynthetic pathway.
  • MR proteins having functional differences from the wild-type MR proteins. These proteins may be improved in efficiency or activity, may be present in greater numbers in the cell than is usual, or may be decreased in efficiency or activity.
  • the invention provides methods for screening molecules which modulate the activity of an MR protein, either by interacting with the protein itself or a substrate or binding partner of the MR protein, or by modulating the transcription or translation of an MR nucleic acid molecule of the invention.
  • a microorganism expressing one or more MR proteins of the invention is contacted with one or more test compounds, and the effect of each test compound on the activity or level of expression of the MR protein is assessed.
  • Such changes in activity may directly modulate the yield, production, and/or efficiency of production of one or more fine chemicals from C. glutamicum, e . g. , methionine.
  • a positive regulator of methionine biosynthesis e.g., RXN02910
  • RXN02910 which activates the transcription or translation of a gene encoding a biosynthetic protein for a desired fine chemical
  • impairing or abrogating the activity of an MR protein e.g., a negative regulator of methionine biosynthesis, e . g.
  • RXA00655 which represses the transcription or translation of such a gene, one may also increase the activity or rate of activity of that biosynthetic pathway.
  • an MR protein such that it constitutively posttranslationally inactivates a protein involved in a degradation pathway for a desired fine chemical, or by altering the activity of an MR protein such that it constitutively represses the transcription or translation of such a gene, one may increase the yield and/or rate of production of the fine chemical from the cell, due to decreased degradation of the compound.
  • MR protein which represses the synthesis of molecules necessary for cell membrane production in response to high levels of waste products in the extracellular medium (in order to block cell growth and division in suboptimal growth conditions) such that it no longer is able to repress such synthesis
  • Such enhanced growth or viability should also increase the yields and/or rate of production of a desired fine chemical from fermentative culture, due to the relatively greater number of cells producing this compound in the culture.
  • the aforementioned mutagenesis strategies for MR proteins to result in increased yields of a fine chemical, e . g. , methionine, from C.
  • the nucleic acid and protein molecules of the invention may be utilized to generate C. glutamicum or related strains of bacteria expressing mutated MR nucleic acid and protein molecules such that the yield and/or efficiency of production of a desired compound is improved.
  • This desired compound may be any natural product of C. glutamicum, which includes the final products of biosynthesis pathways and intermediates of naturally-occurring metabolic pathways, as well as molecules which do not naturally occur in the metabolism of C. glutamicum, but which are produced by a C. glutamicum strain of the invention.
  • the MR molecules of the invention may also be used to identify an organism as being Corynebacterium glutamicum or a close relative thereof. Also, they may be used to identify the presence of C. glutamicum or a relative thereof in a mixed population of microorganisms.
  • the invention provides the nucleic acid sequences of a number of C. glutamicum genes; by probing the extracted ge- nomic DNA of a culture of a unique or mixed population of microorganisms under stringent conditions with a probe spanning a region of a C. glutamicum gene which is unique to this organism, one can ascertain whether this organism is present.
  • the nucleic acid and protein molecules of the invention may also serve as markers for specific regions of the genome. This has utility not only in the mapping of the genome, but also for functional studies of C. glutamicum proteins. For example, to identify the region of the genome to which a particular C. glu- tamicum DNA-binding protein binds, the C. glutamicum genome could be digested, and the fragments incubated with the DNA- binding protein. Those which bind the protein may be additionally probed with the nucleic acid molecules of the invention, preferably with readily detectable labels; binding of such a nu- cleic acid molecule to the genome fragment enables the localization of the fragment to the genome map of C.
  • nucleic acid molecules of the invention may be sufficiently homologous to the sequences of related species such that these nucleic acid molecules may serve as markers for the construction of a genomic map in related bac- teria, such as Brevibacterium lactofermentum.
  • a culture of Corynebacterium glutamicum was grown overnight at 30°C with vigorous shaking in BHI medium (Difco) .
  • the cells were harvested by centrifugation, the supernatant was discarded and the cells were resuspended in 5 ml buffer-I (5% of the original volume of the culture — all indicated volumes have been calculated for 100 ml of culture volume) .
  • Composition of buffer-I 140.34 g/1 sucrose, 2.46 g/1 MgS0 4 x 7H 2 0, 10 ml/1
  • KH 2 P0 4 solution 100 g/1, adjusted to pH 6.7 with KOH
  • 50 ml/1 M12 concentrate 10 g/1 (NH 4 ) 2 S0 4 , 1 g/1 NaCI, 2 g/1 MgSO Register x 7H 2 0, 0.2 g/1 CaCl 2 , 0.5 g/1 yeast extract (Difco), 10 ml/1 trace- elements-mix (200 mg/1 FeS0 4 x H 2 0, 10 mg/1 ZnSO, x 7 H 2 0, 3 mg/1 MnCl. x 4 H 2 0, 30 mg/1 H.BO. 20 mg/1 CoCl.
  • x 6 H 2 0, 1 mg/1 NiCl 2 x 6 H 2 0, 3 mg/1 Na 2 MoOplace x 2 H 2 0, 500 mg/1 complexing agent (EDTA or critic acid), 100 ml/1 vitamins-mix (0.2 mg/1 biotin, 0.2 mg/1 folic acid, 20 mg/1 p-amino benzoic acid, 20 mg/1 riboflavin, 40 mg/1 ca-panthothenate, 140 mg/1 nicotinic acid, 40 mg/1 pyri- doxole hydrochloride, 200 mg/1 myo-inositol) . Lysozyme was added to the suspension to a final concentration of 2.5 mg/ml.
  • EDTA or critic acid 100 ml/1 vitamins-mix (0.2 mg/1 biotin, 0.2 mg/1 folic acid, 20 mg/1 p-amino benzoic acid, 20 mg/1 riboflavin, 40 mg/1 ca-panthothenate, 140 mg/1 nicotinic acid, 40 mg/1 pyri-
  • the cell wall was degraded and the resulting protoplasts are harvested by centrifugation.
  • the pellet was washed once with 5 ml buffer-I and once with 5 ml TE-buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8 ) .
  • the pellet was resuspended in 4 ml TE-buffer and 0.5 ml SDS solution (10%) and 0.5 ml NaCI solution (5 M) are added.
  • proteinase K After adding of proteinase K to a final concentration of 200 ⁇ g/ml, the suspen- sion is incubated for ca.18 h at 37°C.
  • the DNA was purified by extraction with phenol, phenol-chloroform-isoamylalcohol and chloroform-isoamylalcohol using standard procedures. Then, the DNA was precipitated by adding 1/50 volume of 3 M sodium acetate and 2 volumes of ethanol, followed by a 30 min incubation at - 20°C and a 30 min centrifugation at 12,000 rpm in a high speed centrifuge using a SS34 rotor (Sorvall) . The DNA was dissolved in 1 ml TE-buffer containing 20 ⁇ g/ml RNaseA and dialysed at 4°C against 1000 ml TE-buffer for at least 3 hours. During this time, the buffer was exchanged 3 times.
  • EXAMPLE 2 CONSTRUCTION OF GENOMIC LIBRARIES IN ESCHERICHIA COLI OF CORYNEBACTERIUM GLUTAMICUM ATCC13032.
  • Any plasmid or cosmid could be used. Of particular use were the plas- mids pBR322 (Sutcliffe, J.G. (1979) Proc. Natl . Acad. Sci . USA,
  • Gene libraries specifically for use in C. glutamicum may be constructed using plasmid pSL109 (Lee, H.-S. and A.
  • Genomic libraries as described in Example 2 were used for DNA sequencing according to standard methods, in particular by the chain termination method using ABI377 sequencing machines (see e.g., Fleischman, R.D. et al . (1995) "Whole-genome Random Sequencing and Assembly of Haemophilus Influenzae Rd. , Science, 269:496-512) .
  • Sequencing primers with the following nucleotide sequences were used: 5 ' -GGAAACAGTATGACCATG-3 ' (SEQ ID NO: 18) or 5'-GTAAAACGACGGCCAGT-3' (SEQ ID NO: 19).
  • In vivo mutagenesis of Corynebacteri m glutamicum can be performed by passage of plasmid (or other vector) DNA through E. coli or other microorganisms (e . g. Bacillus spp. or yeasts such as Saccharomyces cer- evisiae) which are impaired in their capabilities to maintain the integrity of their genetic information.
  • E. coli or other microorganisms e . g. Bacillus spp. or yeasts such as Saccharomyces cer- evisiae
  • Typical mutator strains have mutations in the genes for the DNA repair system (e . g. , mutHLS, mutD, mutT, etc.; for reference, see Rupp, W.D. (1996) DNA repair mechanisms, in: Escherichia coli and Salmonella , p. 2277-2294, ASM: Washington.)
  • Such strains are well known to one of ordinary skill in the art. The use of such
  • Corynebacteria are cultured in synthetic or natural growth media.
  • a number of different growth media for Corynebacteria are both well-known and readily available (Lieb et al . (1989) Appl . Micro- biol . Biotechnol . , 32:205-210; von der Osten et al . (1998; Biotechnology Letters, 11:11-16; Patent DE 4,120,867; Liebl (1992) "The Genus Corynebacterium, in: The Procaryotes, Volume II, Ba- lows, A. et al . , eds. Springer-Verlag) .
  • These media consist of one or more carbon sources, nitrogen sources, inorganic salts, vitamins and trace elements.
  • Preferred carbon sources are sugars, such as mono-, di-, or polysaccharides .
  • sugars such as mono-, di-, or polysaccharides .
  • glucose, fructose, mannose, galactose, ribose, sorbose, ribulose, lactose, maltose, sucrose, raffinose, starch or cellulose serve as very good carbon sources.
  • sugar to the media via complex compounds such as molasses or other by-products from sugar refinement.
  • Other possible carbon sources are alcohols and organic acids, such as methanol, ethanol, acetic acid or lactic acid.
  • Nitrogen sources are usually organic or inorganic nitrogen compounds, or materials which contain these com- pounds.
  • Exemplary nitrogen sources include ammonia gas or ammonia salts, such as NH 4 C1 or (NH 4 ) 2 S0 4 , NH 4 OH, nitrates, urea, amino acids or complex nitrogen sources like corn steep liquor, soy bean flour, soy bean protein, yeast extract, meat extract and others.
  • ammonia gas or ammonia salts such as NH 4 C1 or (NH 4 ) 2 S0 4 , NH 4 OH, nitrates, urea, amino acids or complex nitrogen sources like corn steep liquor, soy bean flour, soy bean protein, yeast extract, meat extract and others.
  • Inorganic salt compounds which may be included in the media include the chloride-, phosphorous- or sulfate- salts of calcium, magnesium, sodium, cobalt, molybdenum, potassium, manganese, zinc, copper and iron.
  • Chelating compounds can be added to the medium to keep the metal ions in solution.
  • Particularly useful chelating compounds include dihydroxyphenols , like catechol or protocatechuate, or organic acids, such as citric acid. It is typical for the media to also contain other growth factors, such as vitamins or growth promoters, examples of which include bio- tin, riboflavin, thiamin, folic acid, nicotinic acid, pantothen- ate and pyridoxin.
  • the exact composition of the media compounds depends strongly on the immediate experiment and is in- dividually decided for each specific case. Information about media optimization is available in the textbook "Applied Microbiol . Physiology, A Practical Approach ( eds . P.M. Rhodes, P.F. Stan- bury, IRL Press (1997) pp. 53-73, ISBN 0 19 963577 3). It is also possible to select growth media from commercial suppliers, like standard 1 (Merck) or BHI (grain heart infusion, DIFCO) or others .
  • All medium components are sterilized, either by heat (20 minutes at 1.5 bar and 121°C) or by sterile filtration.
  • the components can either be sterilized together or, if necessary, separately. All media components can be present at the beginning of growth, or they can optionally be added continuously or batchwise.
  • the temperature should be in a range between 15°C and 45°C
  • the temperature can be kept constant or can be altered during the experiment .
  • the pH of the medium should be in the range of 5 to 8.5, preferably around 7.0, and can be maintained by the addition of buffers to the media.
  • An exemplary buffer for this purpose is a potassium phosphate buffer.
  • Synthetic buffers such as MOPS, HEPES, ACES and others can alternatively or simultaneously be used. It is also possible to maintain a constant culture pH through the addition of NaOH or NH 4 0H during growth. If complex medium components such as yeast extract are utilized, the necessity for additional buffers may be reduced, due to the fact that many complex compounds have high buffer capacities. If a fermen- tor is utilized for culturing the micro-organisms, the pH can also be controlled using gaseous ammonia.
  • the incubation time is usually in a range from several hours to several days. This time is selected in order to permit the maximal amount of product to accumulate in the broth.
  • the disclosed growth experiments can be carried out in a variety of vessels, such as microtiter plates, glass tubes, glass flasks or glass or metal fermentors of different sizes.
  • the microorganisms should be cultured in microtiter plates, glass tubes or shake flasks, either with or without baf- fles.
  • 100 ml shake flasks are used, filled with 10% (by volume) of the required growth medium.
  • the flasks should be shaken on a rotary shaker (amplitude 25 mm) using a speed-range of 100 - 300 rpm. Evaporation losses can be diminished by the maintenance of a humid atmosphere; alternatively, a mathematical correction for evaporation losses should be performed.
  • the medium is inoculated to an OD 600 of 0.5 - 1.5 using cells grown on agar plates, such as CM plates (10 g/1 glucose, 2,5 g/1 NaCI, 2 g/1 urea, 10 g/1 polypeptone, 5 g/1 yeast extract, 5 g/1 meat extract, 22 g/1 NaCI, 2 g/1 urea, 10 g/1 polypeptone, 5 g/1 yeast extract, 5 g/1 meat extract, 22 g/1 agar, pH 6.8 with 2M NaOH) that had been incubated at 30°C Inoculation of the media is accomplished by either introduction of a saline suspension of C. glutamicum cells from CM plates or addition of a liquid preculture of this bacterium.
  • CM plates 10 g/1 glucose, 2,5 g/1 NaCI, 2 g/1 urea, 10 g/1 polypeptone, 5 g/1 yeast extract, 5 g/1 meat extract, 22 g/1 urea, 10 g/1 polypeptone, 5
  • DNA band-shift assays also called gel retardation assays
  • reporter gene assays such as that described in Kolmar, H. et al . (1995) EMBO J. 14: 3895-3904 and references cited therein). Reporter gene test systems are well known and established for applications in both pro- and eukaryotic cells, using enzymes such as beta-galactosidase, green fluorescent protein, and several others .
  • EXAMPLE 7 ANALYSIS OF IMPACT OF MUTANT PROTEIN ON THE PRODUC- TION OF THE DESIRED PRODUCT
  • the effect of the genetic modification in C. glutamicum on production of a desired compound can be assessed by growing the modified microorganism under suitable con- ditions (such as those described above) and analyzing the medium and/or the cellular component for increased production of the desired product (i.e., an amino acid) .
  • suitable con- ditions such as those described above
  • Such analysis techniques are well known to one of ordinary skill in the art, and include spectroscopy, thin layer chromatography, staining methods of various kinds, enzymatic and microbiological methods, and analytical chromatography such as high performance liquid chromatography (see, for example, Ullman, Encyclopedia of Industrial Chemistry, vol. A2 , p. 89-90 and p. 443-613, VCH: Weinheim (1985); Fallon, A.
  • EXAMPLE 8 PURIFICATION OF THE DESIRED PRODUCT FROM C. GLUTAMICUM CULTURE
  • Recovery of the desired product from the C. glutamicum cells or supernatant of the above-described culture can be performed by various methods well known in the art. If the desired product is not secreted from the cells, the cells can be harvested from the culture by low-speed centrifugation, the cells can be lysed by standard techniques, such as mechanical force or sonication. The cellular debris is removed by centrifugation, and the supernatant fraction containing the soluble proteins is retained for further purification of the desired compound. If the product is secreted from the C. glutamicum cells, then the cells are removed from the culture by low-speed centrifugation, and the supernate fraction is retained for further purification.
  • the supernatant fraction from either purification method is subjected to chromatography with a suitable resin, in which the desired molecule is either retained on a chromatography resin while many of the impurities in the sample are not, or where the impurities are retained by the resin while the sample is not.
  • chromatography steps may be repeated as necessary, using the same or different chromatography resins.
  • One of ordinary skill in the art would be well-versed in the selection of appro- priate chromatography resins and in their most efficacious application for a particular molecule to be purified.
  • the purified product may be concentrated by filtration or ultrafiltration, and stored at a temperature at which the stability of the product is maximized.
  • the identity and purity of the isolated compounds may be assessed by techniques standard in the art. These include high- performance liquid chromatography (HPLC), spectroscopic methods, staining methods, thin layer chromatography, NIRS, enzymatic assay, or microbiologically . Such analysis methods are reviewed in: Patek et al . (1994) Appl . Environ . Microbiol . 60: 133-140; Malakhova et al . (1996) Biotekhnologiya 11: 27-32; and Schmidt et al . (1998) Bioprocess Engineer. 19: 67-70. Ulmann's Encyclopedia of Industrial Chemistry, (1996) vol. A27, VCH: Weinheim, p. 89-90, p. 521-540, p.
  • HPLC high- performance liquid chromatography
  • NIRS thin layer chromatography
  • enzymatic assay or microbiologically .
  • Such analysis methods are reviewed in: Patek et al . (1994) Appl . Environ
  • Gapped BLAST can be utilized as described in Altschul et al . , (1997) Nucleic Acids Res . 25 (17) : 3389-3402.
  • the percent homology between two amino acid sequences can also be accomplished using the GAP program in the GCG software pack- age (available at http://www.gcg.com), using either a Blosum 62 matrix or a PAM250 matrix, and a gap weight of 12, 10, 8, 6, or 4 and a length weight of 2, 3, or 4.
  • the percent homology between two nucleic acid sequences can be accomplished using the GAP program in the GCG software package, using standard parame- ters, such as a gap weight of 50 and a length weight of 3.
  • sequences of the invention may additionally be used in the construction and application of DNA microarrays (the design, methodology, and uses of DNA arrays are well known in the art, and are described, for example, in Schena, M. et al . (1995) Sci ence 270: 467-470; Wodicka, L. et al . (1997) Nature Biotechnol ogy 15: 1359-1367; DeSaizieu, A. et al . (1998) Nature Biotech- nology 16: 45-48; and DeRisi, J.L. et al . (1997) Science 278: 680-686) .
  • D ⁇ A microarrays are solid or flexible supports consisting of nitrocellulose, nylon, glass, silicone, or other materials. ⁇ u- cleic acid molecules may be attached to the surface in an ordered manner. After appropriate labeling, other nucleic acids or nucleic acid mixtures can be hybridized to the immobilized nucleic acid molecules, and the label may be used to monitor and measure the individual signal intensities of the hybridized molecules at defined regions. This methodology allows the simultaneous quantification of the relative or absolute amount of all or selected nucleic acids in the applied nucleic acid sample or mixture. D ⁇ A microarrays, therefore, permit an analysis of the expression of multiple (as many as 6800 or more) nucleic acids in parallel (see, e.g., Schena, M.
  • the sequences of the invention may be used to design oligonucleotide primers which are able to amplify defined regions of one or more C. glutamicum genes by a nucleic acid amplification reaction such as the polymerase chain reaction.
  • the choice and design of the 5' or 3' oligonucleotide primers or of appropriate linkers allows the covalent attachment of the resulting PCR products to the surface of a support medium described above (and also described, for example, Schena, M. et al . (1995) Science 270: 467-470) .
  • Nucleic acid microarrays may also be constructed by in si tu oligonucleotide synthesis as described by Wodicka, L. et al . (1997) Na ture Biotechnology 15: 1359-1367.
  • photolithographic methods precisely defined regions of the matrix are exposed to light.
  • Protective groups which are photolabile are thereby activated and undergo nucleotide addition, whereas regions that are masked from light do not undergo any modification. Subsequent cycles of protection and light activation permit the synthesis of different oligonucleotides at defined positions.
  • Small, de- fined regions of the genes of the invention may be synthesized on microarrays by solid phase oligonucleotide synthesis.
  • nucleic acid molecules of the invention present in a sample or mixture of nucleotides may be hybridized to the microarrays.
  • These nucleic acid molecules can be labeled according to standard methods.
  • nucleic acid molecules e.g., mRNA molecules or DNA molecules
  • Hybridization of labeled nucleic acids to microarrays is described ( e . g. , in Schena, M. et al . (1995) supra ; Wodicka, L. et al . (1997), supra ; and DeSaizieu A.
  • Radioactive labels can be detected, for ex- ample, as described in Schena, M. et al . (1995) supra) and fluorescent labels may be detected, for example, by the method of Shalon et al . (1996) Genome Research 6: 639-645).
  • sequences of the invention permits comparative analyses of different strains of C. glutamicum or other Corynebacteria. For example, studies of inter-strain variations based on individual transcript profiles and the identification of genes that are important for specific and/or desired strain properties such as pathogenicity, productivity and stress tolerance are facilitated by nucleic acid array methodologies. Also, comparisons of the profile of expression of genes of the inven- tion during the course of a fermentation reaction are possible using nucleic acid array technology.
  • EXAMPLE 11 ANALYSIS OF THE DYNAMICS OF CELLULAR PROTEIN POPULATIONS (PROTEOMICS)
  • Protein populations of interest include, but are not limited to, the total protein population of C. glutamicum ( e . g. , in comparison with the protein populations of other organisms) , those proteins which are active under specific environmental or metabolic conditions ( e . g. , during fermentation, at high or low temperature, or at high or low pH) , or those proteins which are active during specific phases of growth and development.
  • Protein populations can be analyzed by various well-known techniques, such as gel electrophoresis .
  • Cellular proteins may be obtained, for example, by lysis or extraction, and may be sepa- rated from one another using a variety of electrophoretic techniques.
  • Sodium dodecyl sulfate polyacrylamide gel electrophoresis SDS-PAGE
  • Isoelectric focusing polyacrylamide gel electrophoresis Isoelectric focusing polyacrylamide gel electrophoresis (IEF-PAGE) separates proteins by their isoelectric point (which reflects not only the amino acid sequence but also posttranslational modifications of the protein) .
  • Another, more preferred method of protein analysis is the consecutive combination of both IEF-PAGE and SDS-PAGE, known as 2-D-gel electrophoresis (described, for example, in Hermann et al . (1998) Electro- phoresis 19: 3217-3221; Fountoulakis et al . (1998) Electrophoresis 19: 1193-1202; Langen et al . (1997) Electrophoresis 18: 1184-1192; Antelmann et al . (1997) Electrophoresis 18: 1451- 1463) .
  • Other separation techniques may also be utilized for protein separation, such as capillary gel electrophoresis; such techniques are well known in the art.
  • Proteins separated by these methodologies can be visualized by standard techniques, such as by staining or labeling. Suitable stains are known in the art, and include Coomassie Brilliant Blue, silver stain, or fluorescent dyes such as Sypro Ruby (Molecular Probes) .
  • Suitable stains include Coomassie Brilliant Blue, silver stain, or fluorescent dyes such as Sypro Ruby (Molecular Probes) .
  • the inclusion of radioactively labeled amino acids or other protein precursors e.g., S-methionine, 35 S- cysteine, 1 C-labelled amino acids, 15 N-amino acids, l5 N0 3 or 15 NH 4 * or u C-labelled amino acids
  • fluorescent labels may be employed. These labeled proteins can be extracted, isolated and separated ac- cording to the previously described techniques.
  • Proteins visualized by these techniques can be further analyzed by measuring the amount of dye or label used.
  • the amount of a given protein can be determined quantitatively using, for exam- pie, optical methods and can be compared to the amount of other proteins in the same gel or in other gels. Comparisons of proteins on gels can be made, for example, by optical comparison, by spectroscopy, by image scanning and analysis of gels, or through the use of photographic films and screens. Such tech- niques are well-known in the art.
  • N- and/or C-terminal amino acid sequencing such as Edman degra- dation
  • mass spectrometry in particular
  • EXAMPLE 12 PREPARATION OF A CORYNEBACTERIUM GLUTAMICUM STRAIN DEFICIENT IN THE NEGATIVE REGULATOR OF METHIONINE BIOSYNTHESIS (RXA00655)
  • pS_delta655 (SEQ ID NO: 3) for preparation of a C. glutamicum strain deficient in the negative regulator of methionine biosynthesis (RXA00655) is constructed by ligating PCR amplified fragments of the 5'- and 3' regions of RXA00655 (SEQ ID N0:1) into the vector pCLiK5MCS_integrativ_sacB (SEQ ID NO: 4) using standard methods (Sambrook et al . (1989), Molecular Cloning. A Laboratory Manual, Cold Spring Harbor; Innis et al . (1990) PCR Protocols. A Guide to Methods and Applications, Academic Press) .
  • the PCR amplified 5 '-fragment is flanked at its 5 '-end by a primer-introduced Xhol site and at its 3 '-end by an endogenous
  • the PCR amplified 3 '-fragment is flanked at its 5 '-end by an Nhel site followed by an TAA-stopp codon, which are introduced by the primer, and at its 3 '-end by a primer-introduced Mlul site.
  • pS_delta655 (SEQ ID NO: 3) is electroporated into the C. gl utamicum strain ATCC13032 as described (Liebl et al . (1989) FEMS Microbiol Let 53:299-303). Transformands with via intermolecular homologous recombination integrated plasmid are selected on CM agar plates supplemented with 50 mg/1 kanamycin.
  • Kanamycin-resistant clones are incubated unselectively (without Kanamycin) overnight in CM medium to achieve excision of the plasmid together with the chromosomal copy of RXA00655.
  • the cultures are plated on CM agar containing 10% sucrose. Only those clones in which the integrated pS_delta655 plasmid is excised can grow on CM agar containing sucrose, because the sacB gene in pS_delta655 converts sucrose into levan sucrase, which is toxic for C. glutamicum.
  • the deletion construct of RXA00655 or the chromosomal copy of RXA00655 is eliminated together with the plasmid.
  • chromosomal DNA from all potential clones are prepared (Tauch et al . (1995) Plasmid 33:168-179 or Eikmanns et al . (1994) Microbiology 140:1817-1828) and controlled with a Southern Blot analysis according to Sambrook et al . (1989), Molecular Cloning. A Laboratory Manual, Cold Spring Harbor.
  • the knock-out strain is called ATCC13032_delta_rxa00655.
  • EXAMPLE 15 PREPARATION OF METHIONINE WITH ATCC13032_DELTA_RXA00655
  • the strains ATCC13032 and ATCC13032_delta_rxa00655 are incubated on a CM-agar plate for 2 d at 30°C.
  • the cells are scraped from the plate and suspended in saline.
  • 10 ml medium II and 0.5 g autoclaved CaCO. (Riedel de Haen) in a 100 ml conical flask are inoculated with the cell suspension to a final OD600nm of 1.5. Culturing is carried out at 30°C for 72 h.
  • EXAMPLE 16 PREPARATION OF A CORYNEBACTERIUM GLUTAMICUM STRAIN OVEREXPRESSING THE POSITIVE REGULATOR OF METHIONINE
  • the plasmid named pGrxn2910 (SEQ ID NO: 13) for overexpressing the positive regulator of methionine biosynthesis (RXN02910; SEQ ID NO: 5 or 6) is constructed by ligating a PCR amplified fragment of RXN02910 (SEQ ID NO: 9) into the vector pG (SEQ ID NO: 12) using standard methods (Sambrook et al . (1989), Molecular Cloning. A Laboratory Manual, Cold Spring Harbor; Innis et al . (1990) PCR Protocols. A Guide to Methods and Applications, Aca- demic Press) . The following pair of oligonucleotide primers was used for the amplification:
  • antisense primer SEQ ID NO: 8
  • the PCR amplified fragment is flanked at its 5 '-end by a primer- introduced Xhol site and at its 3 '-end by a primer-introduced Bcul site.
  • the amplified fragments contains the open reading frame (ORF) of RXN02910 with additional 5' regions of the corresponding gene including the promotor.
  • the resulting plasmid pGrxn02910 (SEQ ID NO: 13) is electropo- rated into the C. glutamicum strain ATCC13032 as described (Liebl, et al . (1989) FEMS Microbiology Letters 53:299-303). Transformands are selected on CM agar plates supplemented with 50 mg/1 kanamycin (see above) . The resulting strain is named ATCC13032/pGrxn02910. EXAMPLE 17: PREPARATION OF METHIONINE WITH ATCC13032/PGRXN02910
  • the strains ATCC13032 and ATCC13032/pGrxn02910 are incubated on a CM-agar plate for 2 days at 30°C
  • the cells are scraped from the plate and suspended in saline.
  • 10 ml medium II (see above) and 0.5 g autoclaved CaCO. (Riedel de Haen) in a 100 ml conical flask are inoculated with the cell suspension to a final OD ⁇ OOnm of 1.5. Culturing is carried out at 30°C for 72 h.
  • all plates and cultures contain additional 50 ⁇ g/1 kanamycin.
  • the amount of formed methionine was determined with an Agilent 1100 series LC system HPLC according to a method from Agilent.
  • the with ortho- phtalaldehyde pre-column derivated amino acids are separated on a Hypersil AA-column (Agilent) .
  • the strain ATCC13032/pGrxn02910 produces significantly more methionine than ATCC13032.
  • plntegrativ_delta2910 for preparation of a C. glutamicum strain deficient in the regulator of methionine biosynthesis (rxn02910) is constructed by ligating a PCR amplified fragment of rxn02910 into the vector plntegrativ (SEQ ID NO:14) using standard methods (Sambrook et al . (1989), Molecular Cloning. A Laboratory Manual, Cold Spring Harbor; Innis et al . (1990) PCR Protocols. A Guide to Methods and Applications, Academic Press) .
  • the PCR amplified fragment (SEQ ID NO: 11) is flanked at its 5 '-end by a primer-introduced Xhol site and at its 3 '-end by a primer-introduced EcoRV site.
  • plntegrativ_delta2910 (SEQ ID NO: 15) is electroporated into the C. glutamicum strain ATCC13032 as described (Liebl et al . (1989) FEMS Microbiol Let 53:299-303). Transformands with via intermo- lecular homologous recombination integrated plasmid are selected on CM agar plates supplemented with 50 mg/1 kanamycin. To identify a clone which has an integrated plasmid and thus disrupted the chromosomal copy of RXN02910, chromosomal DNA from potential clones are prepared (Tauch et al . (1995) Plasmid 33:168-179 or Eikmanns et al . (1994) Microbiology 140:1817-1828) and controlled with a Southern Blot analysis according to Sambrook et al . (1989), Molecular Cloning. A Laboratory Manual, Cold Spring Harbor .
  • the knock-out strain is called ATCC13032_delta_rxn02910.
  • the amount of formed methionine was determined with an Agilent 1100 series LC system HPLC according to a method from Agilent.
  • the with ortho-phtalaldehyde pre-column derivated amino acids are separated on a Hypersil AA-column (Agilent) .
  • strain ATCC13032_delta_rxn02910 produces significant less methionine than ATCC13032, thereby demonstrating that rxn02910 is indeed a positive regulator of methionine biosynthesis.
  • NRRL ARS Culture Collection, Northern Regional Research Laboratory, Peoria, IL, USA
  • NCIMB National Collection of Industrial and Marine Bacteria Ltd., Aberdeen, UK

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des molécules d'acides nucléiques, désignées comme molécules d'acides nucléiques MR, codant de nouvelles protéines MR provenant de Corynebacterium glutamicum qui sont impliquées dans la biosynthèse d'un produit chimique de qualité, p.ex. la biosynthèse de méthionine. L'invention concerne également des molécules d'acides nucléiques antisens, des cassettes d'expression transgénique et des vecteurs contenant les molécules d'acides nucléiques MR ainsi que des cellules hôtes dans lesquelles les cassettes d'expression ou vecteurs ont été introduit(e)s. L'invention concerne par ailleurs des procédés de production de méthionine à partir de micro-organismes, p.ex. C. glutamicum, impliquant la mise en culture de micro-organismes recombinants qui surexpriment ou sous-expriment au moins une molécule MR de cette invention dans des conditions telles que la méthionine est produite. Font également l'objet de cette invention des procédés de production d'un produit chimique de qualité, p.ex. la méthionine participant à la mise en culture de micro-organismes recombinants ayant des gènes MR sélectionnés effacés ou ayant muté dans des conditions telles que le produit chimique de qualité, p.ex. la méthionine, est obtenu.
PCT/EP2002/013504 2002-11-29 2002-11-29 Procedes de production de methionine WO2004050694A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CN02829972.8A CN1694899B (zh) 2002-11-29 2002-11-29 生产甲硫氨酸的方法
PCT/EP2002/013504 WO2004050694A1 (fr) 2002-11-29 2002-11-29 Procedes de production de methionine
EP02790458A EP1567549A1 (fr) 2002-11-29 2002-11-29 Procedes de production de methionine
BRPI0215958A BRPI0215958B1 (pt) 2002-11-29 2002-11-29 métodos para produção de metionina
JP2004556063A JP2006521083A (ja) 2002-11-29 2002-11-29 メチオニンの生産方法
AU2002368410A AU2002368410A1 (en) 2002-11-29 2002-11-29 Methods for the production of methionine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2002/013504 WO2004050694A1 (fr) 2002-11-29 2002-11-29 Procedes de production de methionine

Publications (1)

Publication Number Publication Date
WO2004050694A1 true WO2004050694A1 (fr) 2004-06-17

Family

ID=32405659

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/013504 WO2004050694A1 (fr) 2002-11-29 2002-11-29 Procedes de production de methionine

Country Status (6)

Country Link
EP (1) EP1567549A1 (fr)
JP (1) JP2006521083A (fr)
CN (1) CN1694899B (fr)
AU (1) AU2002368410A1 (fr)
BR (1) BRPI0215958B1 (fr)
WO (1) WO2004050694A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006008152A1 (fr) * 2004-07-20 2006-01-26 Basf Ag Micro-organismes pour la production de composes sulfures
DE102008001874A1 (de) * 2008-05-20 2009-11-26 Evonik Degussa Gmbh Verfahren zur Herstellung von L-Aminosäuren
US7718632B2 (en) 2007-06-15 2010-05-18 Novartis Ag RNAi inhibition of alpha-ENaC expression
EP2431476A1 (fr) 2007-02-19 2012-03-21 Evonik Degussa GmbH Bactéries coryneformes dotées d'une activité de division de la glycine
WO2015028674A1 (fr) 2013-08-30 2015-03-05 Metabolic Explorer Micro-organismes pour la production de méthionine ayant une activité de méthionine synthase améliorée et sortie de méthionine

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102254631B1 (ko) * 2021-01-15 2021-05-21 씨제이제일제당 주식회사 신규한 펩타이드 메티오닌 설폭사이드 환원효소 변이체 및 이를 이용한 imp 생산 방법
KR102281359B1 (ko) * 2021-01-26 2021-07-22 씨제이제일제당 (주) 신규한 단백질 변이체 및 이를 이용한 l-발린 생산 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1108790A2 (fr) * 1999-12-16 2001-06-20 Kyowa Hakko Kogyo Co., Ltd. Nouveaux polynuclétides
WO2002097096A2 (fr) * 2001-05-30 2002-12-05 Degussa Ag Sequences nucleotidiques codant pour le gene metd

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10109690A1 (de) * 2000-09-02 2002-03-14 Degussa Neue für das metY-Gen kodierende Nukleotidsequenzen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1108790A2 (fr) * 1999-12-16 2001-06-20 Kyowa Hakko Kogyo Co., Ltd. Nouveaux polynuclétides
WO2002097096A2 (fr) * 2001-05-30 2002-12-05 Degussa Ag Sequences nucleotidiques codant pour le gene metd

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 1 March 2001 (2001-03-01), SEEGER ET AL., XP002246293, Database accession no. Q9EWI2 *
DATABASE EMBL [online] 2 October 2002 (2002-10-02), KAWARABAYASI ET AL.: "Corynebacterium efficiens YS-314 DNA, complete genome, section 10/11.", XP002246294, Database accession no. AP005223 *
KASE H ET AL: "ISOLATION AND CHARACTERIZATION OF S ADENOSYL METHIONINE REQUIRING MUTANTS AND ROLE OF S ADENOSYL METHIONINE IN THE REGULATION OF METHIONINE BIOSYNTHESIS IN CORYNEBACTERIUM-GLUTAMICUM", AGRICULTURAL AND BIOLOGICAL CHEMISTRY, vol. 39, no. 1, 1975, pages 161 - 168, XP009012949, ISSN: 0002-1369 *
KASE H ET AL: "L METHIONINE PRODUCTION BY METHIONINE ANALOG RESISTANT MUTANTS OF CORYNEBACTERIUM-GLUTAMICUM", AGRICULTURAL AND BIOLOGICAL CHEMISTRY, vol. 39, no. 1, 1975, pages 153 - 160, XP009012948, ISSN: 0002-1369 *
OLD I G ET AL: "REGULATION OF METHIONINE BIOSYNTHESIS IN THE ENTEROBACTERIACEAE", PROGRESS IN BIOPHYSICS AND MOLECULAR BIOLOGY, PERGAMON PRESS, OXFORD, GB, vol. 56, no. 3, 1991, pages 145 - 185, XP001057787, ISSN: 0079-6107 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006008152A1 (fr) * 2004-07-20 2006-01-26 Basf Ag Micro-organismes pour la production de composes sulfures
JP2008506408A (ja) * 2004-07-20 2008-03-06 ビーエーエスエフ　アクチェンゲゼルシャフト 硫黄含有化合物を生産するための微生物
JP4648947B2 (ja) * 2004-07-20 2011-03-09 エボニック デグサ ゲーエムベーハー 硫黄含有化合物を生産するための微生物
EP2431476A1 (fr) 2007-02-19 2012-03-21 Evonik Degussa GmbH Bactéries coryneformes dotées d'une activité de division de la glycine
US7718632B2 (en) 2007-06-15 2010-05-18 Novartis Ag RNAi inhibition of alpha-ENaC expression
US7943592B2 (en) 2007-06-15 2011-05-17 Novartis Ag RNAi inhibition of alpha-ENaC expression
US8168606B2 (en) 2007-06-15 2012-05-01 Novartis Ag RNAi inhibition of alpha-ENaC expression
DE102008001874A1 (de) * 2008-05-20 2009-11-26 Evonik Degussa Gmbh Verfahren zur Herstellung von L-Aminosäuren
WO2015028674A1 (fr) 2013-08-30 2015-03-05 Metabolic Explorer Micro-organismes pour la production de méthionine ayant une activité de méthionine synthase améliorée et sortie de méthionine

Also Published As

Publication number Publication date
CN1694899A (zh) 2005-11-09
EP1567549A1 (fr) 2005-08-31
BRPI0215958B1 (pt) 2016-11-08
BR0215958A (pt) 2005-09-13
AU2002368410A1 (en) 2004-06-23
CN1694899B (zh) 2011-07-06
JP2006521083A (ja) 2006-09-21

Similar Documents

Publication Publication Date Title
US8389251B2 (en) Method for producing methionine using a microorganism with reduced expression activity of a negative regulator of methionine biosynthesis
EP1257649B1 (fr) Genes de corynebacterum glutamicum codant pour des proteines de voie metabolique
US7273721B2 (en) Corynebacterium glutamicum genes encoding proteins involved in membrane synthesis and membrane transport
KR100878335B1 (ko) 스트레스 저항성 및 내성 단백질을 코딩하는코리네박테리움 글루타미쿰 유전자
EP2290062A1 (fr) Gène issu de Corynebacterium glutamicum codant pour phosphoenolpyruvat carboxykinase
KR100834985B1 (ko) 항상성 및 적응과 관련된 단백질을 코딩하는코리네박테리움 글루타미쿰 유전자
KR20030002295A (ko) 막 합성 및 막 운반 관련 단백질을 코딩하는코리네박테리움 글루타미쿰 유전자
US7393675B2 (en) Corynebacterium glutamicum genes encoding proteins involved in carbon metabolism and energy production
EP1261718A2 (fr) Genes de corynebacterium glutamicum codant des proteines de voie metabolique
EP1345714A1 (fr) Genes de corynebacterie
EP1246922A2 (fr) Genes de corynebacterium glutamicum codant pour des proteines du systeme de transport des sucres phosphotransferase: phosphoenolpyruvate
EP1567549A1 (fr) Procedes de production de methionine
RU2321634C2 (ru) Гены corynebacterium glutamicum, кодирующие белки, участвующие в метаболизме углерода и продуцировании энергии
RU2304616C2 (ru) Гены corynebacterium glutamicum, кодирующие белки, участвующие в гомеостазе и адаптации
RU2312145C2 (ru) Гены corynebacterium glutamicum, кодирующие белки, участвующие в синтезе мембран и мембранном транспорте
RU2303635C2 (ru) Гены corynebacterium glutamicum, кодирующие белки резистентности и толерантности к стрессам
EP1661987A1 (fr) Gène issu de Corynebacterium glutamicum codant pour phosphoenolpyruvat carboxykinase
EP1634952A2 (fr) Gènes codants pour des protéines de Corynebacterium glutamicum, qui participent à l'homéostasie et à l'adaptation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002790458

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004556063

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002368410

Country of ref document: AU

Ref document number: 1020057009623

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 20028299728

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002790458

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0215958

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 1020057009623

Country of ref document: KR